St. John's University

St. John's Scholar
Theses and Dissertations
2021

SELECTIVE TOXICITY OF MX106-4C, A SURVIVIN INHIBITOR, TO
ABCB1 POSITIVE MULTIDRUG RESISTANT COLON CANCER
Zining Lei

Follow this and additional works at: https://scholar.stjohns.edu/theses_dissertations
Part of the Pharmacy and Pharmaceutical Sciences Commons

SELECTIVE TOXICITY OF MX106-4C, A SURVIVIN INHIBITOR, TO ABCB1
POSITIVE MULTIDRUG RESISTANT COLON CANCER
A dissertation submitted in partial fulfillment
of the requirements for the degree of
DOCTOR OF PHILOSOPHY
to the faculty of the
DEPARTMENT OF PHARMACEUTICAL SCIENCES
of
COLLEGE OF PHARMACY AND HEALTH SCIENCES
at
ST. JOHN'S UNIVERSITY
New York
by
Zining Lei
Date Submitted

_____________________

Date Approved

_____________________

____________________________________

____________________________________

ZINING LEI

JOHN N.D. WURPEL

© Copyright by Zining Lei 2021
All Rights Reserved

ABSTRACT

SELECTIVE TOXICITY OF MX106-4C, A SURVIVIN INHIBITOR, TO ABCB1
POSITIVE MULTIDRUG RESISTANT COLON CANCER

Zining Lei

Multidrug resistance (MDR) is a major challenge in colon cancer chemotherapy,
which is typically mediated by the overexpression of ATP-binding cassette (ABC)
transporters, particularly ABCB1 (P-gp, MDR1). The application of ABCB1 inhibitors to
overcome ABCB1-mediated MDR has been disappointing in the clinical settings. As an
alternative approach, a synthetic analog of survivin inhibitor MX106, MX106-4C, was
identified as a potent collateral sensitivity (CS) agent that selectively exerted more than
10-fold cytotoxicity on ABCB1 positive MDR colon cancer cell lines compared to cell
lines with low ABCB1 expression. Biochemical assays revealed that MX106-4C did not
affect the ATPase activity or the efflux function of ABCB1. Short-term (up to 72 h)
incubation with MX106-4C significantly downregulated ABCB1 expression at the
transcriptional level but not protein level, whereas long-term (14 d) incubation with
MX106-4C significantly downregulated ABCB1 protein expression. These findings
suggest an indirect interaction and regulation between MX106-4C and ABCB1. However,
the selective toxicity of MX106-4C could be reversed by an ABCB1 inhibitor, knockout
of ABCB1, or ABCB1 mutation with impaired function, indicating that the selective

cytotoxicity was ABCB1 expression and function dependent. Therefore, MX106-4C may
interact with an ABCB1-dependent downstream event. Further studies demonstrated that
the selective cytotoxic effects of MX106-4C were associated with cell cycle arrest at
G0/G1 phase and apoptosis, possibly via survivin inhibition and activation of caspases-3/7.
Bioinformatic analysis indicated potential involvement of the p21-CDK6-pRb
phosphorylation pathway in MX106-4C-induced cell cycle arrest. Anti-cancer efficacy and
safety tests demonstrated that MX106-4C had good selectivity against ABCB1 positive
colon cancer cells compared to normal colon cells. The selective toxicity of MX106-4C to
ABCB1 positive colon cancer could be retained in multicellular tumor spheroids that
mimicked in vitro settings. Besides, MX106-4C could exert a cytotoxic effect
synergistically with doxorubicin on ABCB1 overexpressing colon cancer cells, and resensitize ABCB1 positive cells to doxorubicin by reducing ABCB1 expression in cell
population via long term exposure. Overall, this study demonstrates that MX106-4C
selectively kills ABCB1 positive MDR colon cancer cells and indirectly interacts with
ABCB1, which provides a clue for CS compound design and a novel strategy to obviate
ABCB1-mediated colon cancer MDR.
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CHAPTER 1 INTRODUCTION
Colorectal cancer is the third most commonly occurring cancer in males and the second in
females with an estimated 1.15 million new cases and 576,858 deaths occurring in 2020
globally, accounting for 5.8% of all cancer-related deaths (Sung et al., 2021). In the United
States, colorectal cancer ranks third for morbidity and second for mortality among all types
of cancer, of which more than two-thirds of diagnostic cases are colon cancer (Siegel et al.,
2020). The primary curative therapy for colon cancer is surgery, while chemotherapy is a
preferred treatment for metastatic colon cancer (Wu, 2018). Moreover, chemotherapy can
be adopted to combat colon cancer at different clinical stages and used as adjuvant therapy
combined with radiotherapy before or after surgery (Dehal et al., 2018; Labianca et al.,
2010; McQuade et al., 2017; Vargas et al., 2014).

Multidrug resistance (MDR) in cancer, which refers to the reduced responsiveness of
cancer cells to multiple chemotherapeutic drugs that are not structurally or functionally
related (Singh et al., 2017), has been reported extensively in patients with colon cancer,
leading to impairment in the chemotherapy success (Hu et al., 2016). MDR phenotype in
cancer cells can be intrinsic resistance against standard chemotherapy at diagnosis or
acquired by prolonged exposure to chemotherapy (Kartal-Yandim et al., 2016; Singh et al.,
2017). Various mechanisms have been discovered to be involved in MDR of colon cancer,
including instability of chromosome (Lee et al., 2011), mutation of drug target (Holohan
et al., 2013), impaired apoptotic pathways (Hu et al., 2015), and decrease in intracellular
drug level due to reduced drug uptake or increased drug efflux mediated by transporters
(Kozovska et al., 2014). In particular, the upregulated expression of ATP-binding cassette
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(ABC) transporters that function as pumps eliminating drugs from cancer cells is a
predominant cause of colon cancer MDR (Hu et al., 2016; Kozovska et al., 2014).

The ABC transporter superfamily consists of 49 members categorized into 7 subfamilies,
which are termed from ABCA to ABCG (Mohammad et al., 2018). At least 15 human ABC
transporters have been identified to mediate MDR by facilitating anticancer drugs efflux
out of tumor cells (Li et al., 2016), particularly ABCB1 (P-glycoprotein, P-gp, MDR1),
ABCC1 (multidrug resistance-associated protein 1, MRP1), and ABCG2 (breast cancer
resistance protein, BCRP) (Chen et al., 2016; Hu et al., 2016; Kozovska et al., 2014; Robey
et al., 2018). Among these members, ABCB1 is one of the most common contributors to
MDR in colon cancer.

ABCB1 is extensively expressed in various types of tissues, particularly at a high level in
the epithelial cells of the colon, small intestine, kidney proximal tubules, bile ducts, and
pancreatic ducts (Holohan et al., 2013). Human ABCB1 is a homodimer transmembrane
glycoprotein with two monomers each including a transmembrane domain (TMD) with six
transmembrane α-helices and a nucleotide-binding domain (NBD) where ATP is bound
and hydrolyzed. ATP hydrolysis is essential for drug transport of ABCB1 from the
intracellular to the extracellular side of the cell (Nandigama et al., 2019). As illustrated in
Figure 1, the catalytic cycle of ABCB1 drug efflux involves substrate binding at the drugbinding pocket at TMDs, closure of TMDs inward, and binding of two ATP molecules to
NBDs leading to dimerization of NBDs, Subsequently, TMDs open outward excreting the
substrate, and ATP molecules are hydrolyzed providing energy for the protein
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conformational change from inward to outward as well as for the reset to the rest status (Li
et al., 2016; Wang et al., 2021). With a vast spectrum of substrates, ABCB1 plays an
important physiological role in protecting tissues by extruding various xenobiotics and
toxicants (International Transporter et al., 2010). On the other hand, tumors that originated
from tissues with ABCB1 expressions, such as colorectal epithelium, gain intrinsic
resistance to many widely used chemotherapeutic drugs that are ABCB1 substrates, such
as doxorubicin, paclitaxel, and vincristine (Fu & Arias, 2012; Meschini et al., 2000).
ABCB1 expression can also be induced in cancer cells by long-term exposure to
chemotherapeutic agents (Ghanbarian et al., 2018; Harmsen et al., 2010), and up-regulation
of ABCB1 expression has been associated with developed MDR during the course of
cancer chemotherapy (Hu et al., 2016; Kathawala et al., 2015).

Figure 1. Catalytic cycle of drug efflux by ABCB1.

A variety of strategies to overcome ABCB1-mediated MDR have been investigated,
including the development of drugs with a novel mechanism of action to bypass resistance
and the development of novel ABCB1 inhibitors that block efflux and restore drug
accumulation when given with anti-cancer drugs (Mohammad et al., 2018; Zhang et al.,
2021). In particular, the reversal of MDR by ABCB1 modulators has been extensively
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investigated. Three generations of small molecule ABCB1 inhibitors and some natural
products considered as the fourth generation ABCB1 inhibitors have been developed (De
Vera et al., 2019; Efferth et al., 2020). The first generation of ABCB1 inhibitors such as
verapamil (Futscher et al., 1996) and cyclosporine A (Egashira et al., 1999) had a relatively
low affinity and selectivity to ABCB1, making the dosages required for ABCB1 inhibition
likely to cause toxicity and side effects (Dong et al., 2020). The second generation of
ABCB1 inhibitors was majorly developed by structural modification based on the firstgeneration inhibitors of ABCB1 (Palmeira et al., 2012). Examples of the second-generation
ABCB1 modulators include dexverapamil, which was derived from verapamil (Dagenais
et al., 2001), and valspodar (PSC 833), an analog of cyclosporin A (Egashira et al., 1999).
These drugs had a higher potency, better ABCB1 selectivity, and lower toxicity compared
to the first generation, however, they also had significant inhibitory effects on cytochrome
P450 enzymes, thereby increasing the likelihood of problematic drug-drug interactions
with the co-administrative chemotherapeutic drugs (Gottesman et al., 2009; Li et al., 2016).
The third generation ABCB1 inhibitors, such as zosuquidar (LY335979) (Sandler et al.,
2004) and tariquidar (XR9576) (Patel et al., 2011), were developed on the basis of
quantitative structure-activity relationship (QSAR) analysis to improve potency and
minimize effects on cytochrome P450 enzymes (Nobili et al., 2006; Silva et al., 2015).
Despite promising pre-clinical results demonstrated for third-generation ABCB1 inhibitors,
subsequent clinical trials turned out to be disappointing due to the intrinsic toxicity or
absence of improvements on the overall survival of patients (Coley, 2010; Cripe et al.,
2006). Furthermore, natural products such as curcumin, flavonoids, alkaloids, and marine
sponge extracts that have shown inhibitory effects on ABCB1 function are generally
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considered as the fourth generation ABCB1 modulator (Kumar & Jaitak, 2019). Several
natural products with ABCB1 inhibiting efficacy, such as tetrandrine and macrolide
eribulin mesylate, have been advanced to clinical trials for MDR modulation where results
are awaited (Abraham et al., 2012; N & K, 2018). Currently, none of the ABCB1 inhibitors
has been approved by the Food and Drug Administration (FDA) as a combination of a
chemotherapeutic drug. Therefore, alternative approaches are urgently needed to
circumvent or resolve cancer MDR mediated by ABCB1.

In the past decade, the discovery of small molecules that have selective toxicity against
ABCB1-expressing cells but not the non-resistant parental cells, a characteristic known as
collateral sensitivity (CS), has introduced an alternative strategy to surmount MDR in
ABCB1 positive cancer (Efferth et al., 2020; Hall et al., 2009; Pluchino et al., 2012). The
identification of CS compounds with high selectivity and potency may help prevent MDR
when used with chemotherapeutic drugs, or re-sensitize MDR tumors to conventional
treatment regimens by selectively killing MDR cells in a heterogeneous tumor population
(Pluchino et al., 2012). However, research discoveries of CS are still rather limited, and
the complex mechanisms of action of CS compounds have not been elucidated due to
insufficient experimental evidence. Major mechanisms identified for the action of CS
agents include 1) reactive oxygen species (ROS) production by futile hydrolysis of ATP,
2) inhibition of ATP production, and 3) induction of plasma membrane perturbation
(Efferth et al., 2020).
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Verapamil was first recognized as a re-sensitizing agent against ABCB1-mediated MDR
when co-administrated with chemotherapeutic agents. In 1986, Warr et al. first reported
that verapamil showed to be a CS agent by exerting higher toxicity to ABCB1
overexpressing vincristine-resistant subline of Chinese hamster ovary (CHO) cells (VCR/T
subline) in the absence of other cytotoxic agents (Warr et al., 1986). Albeit that verapamil
is more toxic to the ABCB1 overexpressing VCR/T subline, the accumulation of verapamil
in VCR/T cells was found lower than that in parental CHO cells due to the efflux of
verapamil by ABCB1, and the CS effect was found to be independent of verapamil’s
function on blocking calcium channel, indicating that the CS effect may be related to
verapamil-ABCB1 interaction (Cano-Gauci & Riordan, 1987; Warr et al., 1986). Further
studies revealed that the selective cytotoxicity on ABCB1 overexpressing cells mediated
by verapamil was dependent on ABCB1 ATPase function and expression of ABCB1
(Karwatsky et al., 2003; Laberge et al., 2009). Based on the dual role of verapamil as a
substrate as well as an inhibitor of ABCB1, which both can stimulate ATPase activity of
ABCB1, it had been hypothesized that verapamil may induce the CS effect by causing
futile hydrolysis of ATP leading to ROS production and depletion of ATP (Callaghan et
al., 2014; Karwatsky et al., 2003; Laberge et al., 2009). Although the CS effect of verapamil
has been only observed in CHO cells but not in human cancer cells, and the cardiac toxicity
of verapamil has limited its usage in reversing cancer MDR under clinical setting, the
discovery of the CS effect on ABCB1 positive cells gave a new idea on targeting ABCB1
overexpressing MDR cancer. More CS agents have been discovered and reported in the
past 10 years, which has promoted a deeper understanding of the mechanism for CS effects
against ABCB1 positive cancer and further facilitated the development of this novel
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approach for combating ABCB1-mediated cancer MDR. Unsurprisingly, different CS
agents can have different types of interaction with ABCB1 to reach the same outcome-selectively killing ABCB1 overexpressing cancer cells. Nakagawa-Goto and colleagues
have demonstrated that desmosdumotin B and its analogs were able to selectively kill
vincristine-selected ABCB1 positive human epidermoid cancer cells (Nakagawa-Goto et
al., 2008) and liver cancer cells (Kuo et al., 2011). Similar to verapamil, the CS effect of
desmosdumotin B has been shown to rely on the expression of functional ABCB1
(Nakagawa-Goto et al., 2010). However, as a flavonoid derivative, desmosdumotin B was
considered to have an inhibitory effect on ABCB1 ATPase and reduce ABCB1 drug efflux
activity (Sun et al., 2009). Further study revealed that desmosdumotin B derivatives may
induce selective toxicity through directly interacting with ABCB1 thereby inhibiting
downstream mTOR pathways and downregulating molecular chaperone GRP78 (Kuo et
al., 2011). ROS production has been suggested as an important mechanism for CS agents,
but the cause of ROS production can be more complex than simply inducing futile ATP
hydrolysis. Dp44mT (di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone) is a redoxactive agent which can induce hydroxyl radicals by chelating iron (Lovejoy et al., 2011).
It has been shown that Dp44mT was selectively toxic to multiple types of ABCB1 positive
MDR cancer in vitro and in vivo by “hijacking” lysosomal ABCB1 as an ABCB1 substrate,
which enables the compound to enter lysosome and induce oxidative stress in the lysosome
resulting in cell death (Jansson et al., 2015). Some CS agents may exert selective toxicity
without having direct interaction with ABCB1. An example is NSC73306 and its analogs,
which have been demonstrated to produce ABCB1-dependent CS effects on various types
of cancer cells expressing endogenous or selection-induced ABCB1 expression, without
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affecting ABCB1 ATPase or ABCB1 efflux activity (Ludwig et al., 2006). Heffeter et al.
(2007) have also reported a lanthanum compound KP772 that had CS effects against
ABCB1 overexpressing cancers without direct interaction with ABCB1 (Heffeter et al.,
2007). However, the precise mechanism of action for NSC73306 and KP772 has not been
fully elucidated.

MX106 is a recently developed survivin inhibitor with potent anti-cancer efficacy (Wang
et al., 2018; Xiao et al., 2015). Recently, in examining the anti-cancer effects of synthesized
analogs of MX106, we unexpectedly found that MX106 and a number of its analogs
exhibited CS by killing ABCB1-overexpressing MDR colon cancer cells, SW620/Ad300,
selectively over the parental drug-sensitive cells, SW620 (Xiao et al., 2017). Among those
compounds,

MX106-4C

(5-(((2-bromo-4-methylbenzyl)oxy)methyl)-7-(pyrrolidine-l-

ylmethyl)quinolin-8-ol)) (Figure 2) has been identified as a leading compound with the
most potent selective toxicity against ABCB1 positive colon cancer cells. The preliminary
findings suggested that MX106-4C may not directly interfere with ABCB1 function as a
substrate or an inhibitor since it did not affect ABCB1 ATPase activity or substrate efflux
function. Although the observed characteristics of MX106-4C are similar to two other CS
compounds against ABCB1, NSC73306 and KP772, there may be a tremendous difference
in how the compound affects ABCB1-dependent biological events according to the
reported mechanism variations from previously discovered CS agents. Therefore, it is
necessary to undertake mechanistic studies to elucidate how MX106-4C exert selective
toxicity and to explore its therapeutic potential in ABCB1-mediated MDR colon cancer.
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Figure 2. Chemical structures of MX106 and MX106-4C.

Survivin (BIRC5), which is the smallest member of the inhibitor-of-apoptosis proteins
(IAPs) family, is frequently overexpressed in various cancers and has been associated with
chemoresistance and poor prognosis in cancer patients (Altieri, 2015; Peery et al., 2017).
The oncogenic roles of survivin mainly depend on its function of inhibiting apoptosis such
as inhibiting the activation of caspases-3 and 7 and regulating mitosis by affecting cell
cycle via binding to CDK4 (Garg et al., 2016). Increased Survivin correlates with poor
prognosis, tumor recurrence, and drug resistance in various human cancers (Coumar et al.,
2013; Zaffaroni & Daidone, 2002). Therefore, the elevated expression of survivin in most
cancer cells makes it an attractive target for cancer treatment. It has been reported that
survivin may interact with ABCB1. Souza et al. discovered cytoplasmic co-localization of
ABCB1 and survivin in leukemia cells, suggesting a functional association between these
two proteins in apoptosis control (Souza et al., 2011). Liu et al have demonstrated that
overexpression of survivin in human breast adenocarcinoma cells MCF-7 reduced
doxorubicin accumulation in cells with upregulation of ABCB1 mRNA level, whilst down
regulation of survivin in its doxorubicin-resistant cell line MCF-7/ADR could
9

downregulate ABCB1 mRNA level and increase the drug accumulation thereby resensitizing cells to doxorubicin (Liu et al., 2010). However, Shi et al. (2007) found that the
protein expression level of ABCB1 was not affected by upregulating or down regulating
survivin in KB cell line, MCF-7 cell line, and their corresponding ABCB1 overexpressing
MDR cell lines KBv200 and MCF-7/ADR, which suggested that survivin in MDR cancer
cells may not interact with ABCB1 directly (Shi et al., 2007). Similarly, inhibition of
ABCB1 was found to downregulate the transcription activity of survivin but not the protein
level, indicating that there may be other pathways associating survivin and ABCB1
indirectly in MDR cancer (Liu et al., 2010). It is worthwhile to ascertain whether there is a
possible mechanism of action of MX106-4C on ABCB1 via modulating survivin.

Therefore, the main aims of this project are: 1) to elucidate the mechanism of action of
MX106-4C in ABCB1 positive colon cancer cells, including ROS production, the
interaction with ABCB1, survivin, and the possible interplay between ABCB1 and survivin
involved inducing cell death; 2) to evaluate the efficacy of MX106-4C using coadministrative treatment with anti-cancer drugs or as a re-sensitizing agent in colon cancer
cells. Shedding light on the mechanisms of action and the anti-cancer efficacy for
compound MX106-4C can provide information for CS compound design and potential
therapeutic interventions for drug resistant colon cancer.
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CHAPTER 2 MATERIALS AND METHODS
2.1

Chemicals and Reagents

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and 0.25%
trypsin-EDTA were purchased from Corning Inc. (New York, NY). Eagle's minimum
essential medium (EMEM) was purchased from ATCC (American Type Culture Collection,
Manassas, VA). Doxorubicin, tariquidar, formaldehyde, Triton X-100, 3-(4, 5dimethylthiazol-yl)-2, 5-diphenyltetrazolium bromide (MTT), agarose, N-acetylcysteine,
and the mouse monoclonal antibody (mAb) for ABCB1 (clone F4) were purchased from
Sigma Chemical Co. (St. Louis, MO). Geneticin (G418) and cisplatin were obtained from
Enzo Life Sciences (Farmingdale, NY). The radiolabeled drug [3H]-paclitaxel (31 Ci/mmol)
was ordered from Moravek Biochemicals, Inc. (Brea, CA). Annexin V-FITC, annexin-V
binding buffer, and PI/RNase staining buffer were from BD Biosciences (San Jose, CA).
The primary antibodies for survivin (clone 71G4B7 rabbit mAb), p53 (clone 1C12 mouse
mAb), p21 (clone 12D1 rabbit mAb), CDK4 (clone D9G3E rabbit mAb), CDK6 (clone
D4S8S rabbit mAb), cyclin D1 (clone E3P5S rabbit mAb), pRb (clone 4H1 mouse mAb),
phosphorylated pRb (Ser807/811, rabbit mAb), and β-actin (clone 13E5 rabbit mAb), and
the horseradish peroxidase-conjugated secondary antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Phosphate buffer saline (PBS), dimethyl sulphoxide
(DMSO), Trizol reagent, the mouse mAb for glyceraldehyde phosphate dehydrogenase
(GAPDH clone G1AR), the Alexa Fluor 488-labeled secondary antibody (anti-mouse),
4,6-diamidino-2-phenylindole (DAPI), and other reagents were ordered from Thermo
Fisher Scientific Inc. (Rockford, IL).
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2.2

Cell Lines and Cell Culture

The HCT-15 cell line originated from human colon adenocarcinoma was purchased from
ATCC (American Type Culture Collection, Manassas, VA). The human colon
adenocarcinoma SW620 and SW620/Ad300 cell lines were kind gifts from Dr. Susan E.
Bates (Columbia University, NY) and Dr. Robert W. Robey (NCI, NIH, MD). The druginduced ABCB1 overexpressing SW620/Ad300 cell line was derived from the parental
SW620 cell line after prolonged exposure to gradually increasing concentration of
doxorubicin up to 300 ng/mL (Lai et al., 1991). The human epidermoid carcinoma cell line
KB-3-1 and the derived ABCB1 overexpressing KB-C2 cell line were kindly provided by
Dr. Shinichi Akiyama (Kagoshima University, Japan). The KB-C2 cell line was established
from the KB-3-1 cell line by a step-wise selection of KB-3-1 in increasing concentrations
of colchicine up to 2 μg/mL (Akiyama et al., 1985). All of the aforementioned cell lines
were cultured in 10% FBS-supplemented DMEM with the addition of 100 unit/mL
penicillin/streptomycin. The SW620/Ad300 and KB-C2 cell lines were respectively
maintained in a complete culture medium containing 300 ng/mL doxorubicin or 2 μg/mL
colchicine, which were switched to drug-free medium at least 2 weeks before experiments.
The stably transfected cell lines HEK293/pcDNA 3.1 and HEK293/ABCB1, which were
established by transfecting HEK293 cells with either the empty pcDNA3.1 vector or the
vector containing full-length ABCB1, were gifts from Dr. Robert W. Robey (NCI, NIH,
MD). The transfected cell lines were cultured in 10% FBS-supplemented DMEM with the
addition of the selective agent G418 (2 mg/mL). The human normal colon fibroblast CCD18Co cell line was generously given by Dr. Diane Hardej (St. John’s University, NY). The
CCD-18Co cells were cultured in EMEM supplemented with 10% FBS and 100 unit/mL
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penicillin/streptomycin. All cell lines were cultured in a 37℃ humidified incubator
containing 5% CO2.

In addition, the HeLa S3 cell models with or without the expression of wildtype (WT)
ABCB1 or mutated ABCB1, including untransduced HeLa S3 cell line, HeLa S3 cells
transiently transduced with WT ABCB1, TM6,12-14A, and TM6,12-14A-EQ mutants,
respectively, were used to study the role of functional ABCB1 in the selective toxicity of
MX106-4C. The ABCB1 TM6,12-14A mutant, which was established by substituting a
group of 14 conserved residues, including seven in both transmembrane helixes 6 and 12,
with alanine, has impaired efflux and acquired uptake function, while the TM6,12-14AEQ mutant has two more mutants at residue E556 and E1201 (both are substituted with
glutamine) at NBD region required for ATP hydrolysis leading to deficient ATPase
function of ABCB1 (Sajid et al., 2020). Due to the unstable transduced models and
limitation on material transferring, experiments involving these cell models, as described
in section 2.3, were performed by Drs. Suresh V. Ambudkar and Hadiar Rahman in
National Cancer Institute.

2.3

Cytotoxicity Assay and Combinational Administration Studies

The MTT assay was performed to determine the ability of compound MX106-4C to
circumvent ABCB1-mediated drug resistance. Cells were seeded at a density of 5000
cells/well into 96-well plates and cultured overnight. Then, various concentrations of
compound MX106-4C were added respectively to the cells for a 72-h incubation. At the
last 4 h of incubation, 20 µL of the MTT solution (4 mg/mL) was added into each well. At
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the end of incubation, the medium was replaced by 100 µL of DMSO to dissolve the
formazan crystals. The plates were well shaken for 10 min, and the absorbance was
determined at 570 nm using AccuSkan™ GO UV/Vis Microplate Spectrophotometer
(Fisher Sci., Fair Lawn, NJ). The half-maximal inhibitory concentration (IC50) values were
calculated from the concentration-response curve to represent the cytotoxicity of the
compound. The fold of drug resistance was calculated by dividing the IC50 value obtained
from the ABCB1 overexpressing cells by that from the parental cell line. Doxorubicin and
cisplatin were also tested as ABCB1 substrate and non-substrate controls, respectively. In
addition, YM155, a survivin inhibitor that is known as an ABCB1 substrate (Radic-Sarikas
et al., 2017), was tested to compare with the cytotoxicity of MX106-4C in ABCB1
overexpressing cells.

In tests involving long-term (14 days) exposure, 50000 cells were seeded into a T25 flask
and incubated in the growth medium for 24 h to ensure adherence before starting treatment.
During the 14-day treatment, the culture medium was replaced with a fresh medium
containing 100 nM MX106-4C every 2-3 days. Cells were allowed to recover in a drugfree medium after treatment until 70% confluency was reached, then cells were harvested
and seed onto 96-well plates for cytotoxicity assay.

Cytotoxicity assays with HeLa S3 cells expressing ABCB1, TM6,12-14A, or TM6,1214A-EQ mutant were conducted by incubating the cells in 96-well plate with various
concentrations of compound MX106-4C for 48 h at 37°C, followed by cell viability test
using Cell Titer Glo reagent kit (Promega). Briefly, 100 µL of CellTiter-Glo reagent was
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added to each well followed by 2-min shaking to mix and 10-min incubation at room
temperature. Then, the generated luminescence was measured, and the percentage of the
control group was used to represent percent survival.

For reversal study, cells were treated with varying concentrations of MX106-4C,
doxorubicin, or cisplatin, with or without adding 1 µM tariquidar 2 h before the treatment
started. MTT assay was conducted at the end of the treatment and the IC50 values of a
compound with or without co-administration of tariquidar were compared to measure the
reversal effect. For drug combination experiments, cells were co-treated with different
concentrations of MX106-4C and doxorubicin for 72 h. The cell viability was determined
by MTT assay as mentioned in the previous paragraph, and the inhibitory effect of each
combination was measured by the percentage of cell viability reduction compared to the
control group. The data was further analyzed using CompuSyn software (ComboSyn Inc,
Paramus, NJ). The combination index (CI) was calculated based on the Chou-Talalay
method (Chou, 2010): CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (Dx)1 and (Dx)2 represented
concentrations of MX106-4C and doxorubicin alone to inhibit x% of cell viability while
(D)1 and (D)2 were concentrations of MX106-4C and doxorubicin in combination to exert
the same effect, respectively. Synergism, additive effect, and antagonism were indicated
by CI < 1, =1, and >1, respectively.

2.4

Analysis of Intracellular Accumulation of Compound MX106-4C

SW620 and SW620/Ad300 cells were seeded into 10 cm culture dishes at a density of 5 ×
106 cells per dish and incubated for 24 h. Then, cells were incubated with complete growth
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medium containing vehicle control or 1 µM compound MX106-4C for 2 h and 4 h,
respectively. After incubation, cells were washed with PBS three times and harvested by
trypsinization. The cell suspensions were centrifuged at 1000 rpm for 5 min and further
washed three times with PBS. The cell pellets were lysed in 200 µL ice-cold methanol
(>99%) by vortex-mixing for 2 min followed by centrifuge at 12000 rpm for 4 min. The
supernatant was subjected to further preparation for LC-MS/MS analysis, meanwhile, the
pellet was dissolved with 1 mL 0.3 M NaOH and subjected to protein quantification using
Bradford assay. The supernatant of each sample was filtered through a 0.2-µm filter. Then,
20 µL of the supernatant were mixed with 20 µL of internal standard working solution and
100 µL of acetonitrile. A 2 µL aliquot of the mixture was injected into the LC-MS/MS
system. ABI-231 was used as an internal standard compound for quantitative analysis. The
LC-MS/MS detection was performed by Dr. Dejian Ma at the University of Tennessee
Health Science Center. The compound concentration was normalized by the pellet protein
quantity.

2.5

ABCB1 ATPase Assay

The ABCB1 ATPase assay was performed using prepared ABCB1 crude membranes
vesicles of High-five insect cells as previously described (Ambudkar, 1998). Briefly, the
ABCB1 membrane vesicles were incubated in ATPase assay buffer with or without 0.3
mM sodium orthovanadate (Na3VO4), which is an inhibitor of ABCB1 ATPase. Various
concentrations of compound MX106-4C or paclitaxel (0 – 10 µM) were added to incubate
with the membranes at 37℃ for 5 min. Then, the ATPase reaction was initiated by adding
5 mM of Mg-ATP. After incubation for 20 min at 37°C, 100 μL 5% SDS solution were
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added to terminate the reaction. The amount of inorganic phosphate released was detected
by spectrophotometry using the phosphomolybdate method. The vanadate-sensitive
ATPase activity due to the ABCB1 transporter was calculated by comparing the released
inorganic phosphate content in samples with and without Na3VO4 treatment.

2.6

[3H]-Paclitaxel Accumulation and Efflux Assay

The effect of compound MX106-4C on the intracellular accumulation and efflux of [3H]paclitaxel was determined in SW620 and SW620/Ad300 cells. Cells were incubated at
37°C in the presence or absence of MX106-4C (50 nM) or tariquidar (50 nM) for 72 h. At
the end of incubation, the cells were harvested, and cell counting was performed using a
hematocytometer. The cell suspensions were diluted to the same density for all groups,
followed by additional 2 h incubation in a medium containing 10 nM [3H]-paclitaxel with
or without MX106-4C or tariquidar. After incubation, cells were washed with ice-cold PBS
then incubated in a medium free of [3H]-paclitaxel, with or without MX106-4C or
tariquidar. At various time points (0, 30, 60, 120 min) cells were harvested and transferred
into scintillation fluid. The radioactivity was detected using the liquid scintillation counter
(Packard Instrument, IL).

2.7

Immunofluorescence Assay

SW620 and SW620/Ad300 cells were seeded at a density of 1 × 105 cells on sterilized glass
coverslips pretreated with 0.1 mg/mL poly-D-lysine in 6-well plates. After 24 h culturing
that enabled the cells to stabilize and attach to the glass coverslip, a 72 h incubation with
vehicle control, 50 or 100 nM MX106-4C was conducted. Thereafter, the cells were
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washed twice with ice-cold PBS and fixed with 4% paraformaldehyde, followed by
permeabilization with 0.25% Triton X-100. Then, the immunofluorescence staining was
performed following the procedures of 1 h blockage with 6% bovine serum albumin (BSA)
in PBS, overnight incubation with the monoclonal antibody against ABCB1 at 4°C, PBS
wash, and 2 h incubation with Alexa Flour 488 rabbit anti-mouse secondary antibody at
room temperature. To counterstain the nuclei, the cells were further incubated with DAPI
solution at room temperature for 15 min. After the staining steps, the coverslip with
attached cells was washed twice with PBS then mounted on a glass slide.
Immunofluorescence images were taken with an EVOS FL Auto Imaging System (Thermo
Fisher Scientific Inc., Rockford, IL).

2.8

Reverse Transcription-Quantitative PCR (RT-qPCR)

Total mRNA of cells was extracted using Trizol reagent following the manufacturer's
protocol. Total RNA concentrations and purity were determined by the optical density (OD)
at 260nm and the ratio of OD260nm/OD280nm. Reverse transcription was performed for
cDNA synthesis. Quantitative gene analysis was performed using the fluorescent dye
SYBR Select Master Mix (Applied Biosystems, Foster City, CA). The primer sequences
are listed in Table 1. The PCR reactions were conducted in Aria Mx Real-Time PCR
System (Agilent Technologies, Santa Clara, CA). The mRNA expression was quantified
using the delta-delta Ct method and normalized by the expression of the GAPDH gene.
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2.9

Western Blotting

Cells were lysed on ice in lysis buffer (10 mM Tris, 1mM EDTA, 150 mM NaCl, 0.1%
SDS, 1% Triton X-100 and protease inhibitor cocktail) for 20 min, followed by
centrifugation at 12,000 x g at 4°C for 20 min. The protein concentration was quantified
using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL). Equal
amounts of total cell lysates were loaded into an SDS-polyacrylamide gel and then
electronically transferred to a polyvinylidene difluoride (PVDF) membrane. The
membrane was blocked in 5% non-fat milk in TBST for 2 h, and then incubated in primary
antibody overnight at 4°C, followed by the incubation in HRP-linked secondary antibody
for 2 h at room temperature. The blocking agent and antibody diluting agent were switched
to 5% BSA in TBST for phosphorylated protein detection to avoid interference from milk
casein. The signal was detected using enhanced chemiluminescence.

2.10

Knockout of ABCB1 Gene in SW620/Ad300 and HCT-15 Cells

A CRISPR/Cas9 system was used to construct the ABCB1 gene knockout subline of
SW620/Ad300 and HCT-15 cell lines, respectively. The custom-designed mammalian
CRISPR vector was purchased from VectorBuilder Inc. (Chicago, IL). The gRNA of the
vector targeting the human ABCB1 gene contains a specific 20 bp guide sequence of 5’CGTAATGCTGACGTCATCGC-3’ selected from exon 16 of the human ABCB1.
Transfection of the ABCB1 targeting vector into SW620/Ad300 and HCT-15 cells was
performed using Fugene6 transfection reagent (Promega, Madison, WI) according to the
manufacturer's instructions. Briefly, SW620/Ad300 cells and HCT-15 cells were seeded in
100 mm dishes with 1 × 106 cells per dish and cultured overnight in DMEM with 10% FBS
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without antibiotics. Then, 8 µg of plasmid DNA was prepared in 376 µL of Opti-MEM
medium and mixed with 24 µL of Fugene6 reagent. After a 30-min incubation at room
temperature, the complex was mixed into the cell culture medium and incubated with the
cells in a culture incubator for 48 h. At the end of incubation, the transfected cells were
rinsed with PBS then incubated with the selection medium containing 1.5 mg/mL G418 for
14 days with the medium changed every three days. Non-transfected cells were used as
negative controls for the selection process. Single colonies of surviving cells were obtained
using the limited dilution method and expanded for further study. The knockout of ABCB1
was further verified by measuring protein expression and mRNA expression levels using
Western blotting and reverse transcription-quantitative PCR analysis, respectively.

2.11

Cell Apoptosis Assay

SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were exposed to MX106-4C
for 0, 24, 48, 72 h, or 100 nM MX106-4C for 72 h. At the end of the exposure period, the
apoptotic cells in each group were detected by flow cytometry using BD Pharmingen FITC
Annexin V apoptosis detection kit following the manufacturer’s instruction. Briefly, cells
were harvested and washed twice with PBS. Then, cells were stained with Annexin VFITC and propidium iodide (PI) in the binding buffer for 15 min in the dark. The
fluorescence was measured for 30000 events per sample using BD Accuri C6 flow
cytometer (BD Biosciences, San Jose, CA) at an excitation wavelength of 488 nm through
FL-1 (533 nm) and FL-2 (585 nm) filters.
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2.12

Cell Cycle Analysis

SW620, SW620/Ad300, SW620/Ad300-ABCB1ko cells were exposed to 50 nM MX1064C for 0, 24, 48, 72 h, or 100 nM MX106-4C for 72 h. At the end of treatment, cells were
harvested and washed twice with ice-cold PBS, followed by a fixation step with ice-cold
70% ethanol for 30 min on ice. After fixation, cells were collected by centrifugation,
washed using PBS, then centrifuged again to remove the supernatant. The cell pellets were
resuspended with 0.5 mL BD Pharmigen PI/RNase stain buffer and incubated in the dark
for 15 min at room temperature. The flow cytometric-based cell cycle analysis was
performed using BD Accuri C6 (BD, Franklin Lakes, NJ) running 30000 events per sample
at a slow rate. The percentage of cells in each cell cycle phase was determined using BD
Accuri C6 software.

2.13

Intracellular ROS Measurement

SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were incubated with 100 nM
MX106-4C for 0, 24, 48, 72 h, or 200 nM MX106-4C with or without 5 mM Nacetylcysteine for 72 h. Subsequently, cells were harvested, washed with PBS, and
incubated with ROS indicator CM-H2DCFDA (10 µM) in the dark for 30 min at 37℃. The
fluorescent product of CM-H2DCFDA generated by the action of intracellular peroxides
was detected by measuring the fluorescence intensity at excitation wavelength 495 nm and
emission wavelength 520 nm using Synergy H1 Hybrid plate reader (BioTek, Winooski,
VT). After reading, the samples were lysed for protein quantification using the BCA assay.
The fluorescence intensity data were normalized by protein content for each sample.
2.14

Intracellular GSH Measurement
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SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were incubated with 100 nM
MX106-4C for 0, 24, 48, 72 h, or 200 nM MX106-4C with or without 5 mM Nacetylcysteine for 72 h. After treatment, cells were harvested using a cell scraper with PBS.
The cell pellets were collected by centrifugation and homogenized using cold MES buffer
(0.2 M 2-(N-morpholino) ethanesulphonic acid, 0.05 M phosphate, and 1 mM EDTA, pH
6.0), followed by centrifuge at 10000 g for 15 min at 4°C. The supernatant was collected
and split into two portions: a half portion was submitted to intracellular total GSH detection
using Cayman’s GSH assay kit (Cayman Chemical Inc., Ann Arbor, MI) according to the
manufacturer’s protocol; the other half portion was subjected to BCA protein quantification
assay for normalization of data.

2.15

Caspases-3/7 Assay

SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were exposed to vehicle
control or 50 or 100 nM of MX106-4C, or a combination of MX106-4C with 1 µM
tariquidar, for 72 h. At the end of incubation, cells were harvested and washed with PBS.
Then, cells were incubated with CellEvent™ Caspase 3/7 Green Detection Reagent
(Invitrogen), and the caspase-3/7 activity was determined by flow-cytometric measurement
on the fluorescence product from cleavage of the detection reagent by active caspases-3/7.
The fluorescence signal was measured 30000 events per sample using BD Accuri C6 flow
cytometer (BD, Franklin Lakes, NJ) at an excitation wavelength of 488 nm through FL-1
(533 nm) filters.

2.16

mRNA Sequencing Analysis
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SW620 and SW620/Ad300 cells were treated with vehicle control or100 nM of MX1064C for 72 h. At the end of treatment, the total RNA of each group was extracted using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Total RNA concentrations and purity
were determined by the OD260nm and the ratio of OD260nm/OD280nm. The quality of
the RNA samples was further assessed by electrophoresis on a denaturing agarose gel to
confirm the integrity of RNA and no DNA contamination. The RNA samples were
subjected to cDNA library construction and Illumina NovaSeq 6000 conducted at
Novogene Corporation Inc. (Durham, NC, USA). The mRNA profiles were compared
between cells incubated with MX106-4C and vehicle, as well as between SW620 and
SW620/Ad300 cells. Differentially expressed genes (DEGs) with a significance level of
p<0.05 and fold change >2 between groups were screened for Kyoto Encyclopedia of
Genes and Genomes KEGG pathway enrichment analysis through performed through the
online

accessible

DAVID

Bioinformatics

Resources

6.8

(NIAID/NIH,

https://david.ncifcrf.gov). Graphical visualizations of data were carried out using
GraphPad Prism 8 software (GraphPad Software, La Jolla, CA) for the volcano plots,
Bioinformatics online platform (http://www.bioinformatics.com.cn/en) for cluster
heatmaps

and

enrichment

bubble

plots,

and

KEGG

Mapper

tool

(https://www.kegg.jp/kegg/mapper) for color-annotated KEGG pathway maps.

2.17

Reverse Phase Protein Array (RPPA)

SW620 and SW620/Ad300 cells were treated with vehicle control or 200 nM of MX1064C for 72 h. After treatment, total protein lysate was prepared, quantified, and gradiently
diluted. The diluted samples were subjected to the RPPA processed by Mills Institute for
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Personalized Cancer Care, Fynn Biotechnologies Ltd. (Shandong, China), including
printing of diluted protein lysates on a nitrocellulose membrane chip, blotting with primary
and secondary antibody, scanning for luminescence signal, and normalization of
expression data. A protein expression file of 307 cancer-related genes was generated for
each treatment group. Identification of DEGs and bioinformatic analysis were carried out
as described in section 2.16.

2.18

Growth and Drug Sensitivity of 3D Multicellular Tumor Spheroids (MCTSs)

Cells were seeded into 1% agarose-coated 96-well plates in a density of 500 cells/well for
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells, and in a density of 1500
cells/well for HCT-15 and HCT-15-ABCB1ko cells. The MCTSs were treated with 300
nM MX106-4C at 48 h post-seeding of the cells when the MCTS aggregates formed to
approximately 300 to 400 µm in diameter. The images of the MCTSs were taken with an
inverted phase-contrast microscope and the diameters of the MCTSs were measured at time
points 0, 24, 48, and 72 h.

2.19

Statistical Analysis

Statistical analysis was carried out in the GraphPad Prism 8 software (GraphPad Software,
La Jolla, CA). Comparisons between mean values of multiple groups were carried out using
one-way ANOVA and the subsequent Tukey’s post hoc test. Dunnett’s post hoc test was
used after ANOVA when multiple groups were compared with one control group.
Comparisons between mean values of HCT-15 cells and HCT-15-ABCB1ko cells were
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carried out using Student’s t-test. A criterion of p value less than 0.05 is set for statistical
significance.
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Table 1. List of primers used for qPCR analysis.
Gene

Forward primer (5’-3’)

Reverse primer (5’-3’)

ABCB1

CTCTTTGCCACAGGAAGCCT

CATTGCGGTCCCCTTCAAGA

ABCB1 (at

ACGTCATCGCTGGTTTCGAT

CTGCATTGTGACAAGTTTGAAGT

BIRC5

TGACGACCCCATAGAGGAAC

CGCACTTTCTCCGCAGTTTC

TP53

TTTGAGGTGCGTGTTTGTGC

TGTTGTTGGGCAGTGCTCG

CDKN1A

TGTCCGTCAGAACCCATGC

AAAGTCGAAGTTCCATCGCTC

CDK4

GTCTATGGTCGGGCCCTCTG

TCAGATCAAGGGAGACCCTCAC

CDK6

TGGCTCTAACCTCAGTGGTCG

GGCAACATCTCTAGGCCAGT

CCND1

GATCAAGTGTGACCCGGACTG

AAAATGCTCCGGAGAGGAGG

FAS

GACCCTCCTACCTCTGGTTCTT

TGTGCAGTCCCTAGCTTTCC

GADD45A

AGAGCAGAAGACCGAAAGGATG TACACCCCGACAGTGATCGT

GADD45B

CCTGCAAATCCACTTCACGC

CGTGTGAGGGTTCGTGACC

GADD45G

GAAAGCGCTGCATGAGTTGC

ATTGTCGGGGTCCACGTTC

GAPDH

CCTCAAGATCATCAGCAATGCC

TCTAGACGGCAGGTCAGGTC

exon 16)
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CHAPTER 3 RESULTS
3.1

Selectively Cytotoxic Effect of Compound MX106-4C against ABCB1

Overexpressing Cells
In order to investigate the selective toxicity of compound MX106-4C against ABCB1
overexpressing cancer cells, two pairs of cell lines consisting of drug-sensitive parental cell
lines and the derived drug-selected ABCB1 overexpressing MDR sublines were tested. As
summarized in Table 2, although anticancer drug doxorubicin and survivin inhibitor YM155 exhibited higher efficacy than MX106-4C in inhibiting the cell viability of parental
cancer cell lines KB-3-1 and SW620, their cytotoxic effects were sharply reduced in MDR
cell lines KB-C2 and SW620/Ad300. On the contrary, MX106-4C showed approximately
10-fold higher potency in ABCB1 overexpressing cell lines KB-C2 and SW620/Ad300
compared to the parental cell line KB-3-1 and SW620. Cisplatin, which is not a substrate
of ABCB1, showed similar sensitivity in drug resistant cells and the parental cells. These
results confirmed that ABCB1 overexpression was the major contributor to the resistance
to substrate drugs doxorubicin and YM-155 in KB-C2 and SW620/Ad300 cells, meanwhile
indicated that MX106-4C may not be a substrate of ABCB1 but selectively toxic to MDR
cells with ABCB1 overexpression.

To further confirm the role of ABCB1 overexpression in the selective toxicity of compound
MX106-4C, ABCB1 gene transfected HEK293/ABCB1 and the vector control
HEK293/pcDNA3.1 cells were subjected to cytotoxicity testing. Similar results were
observed from HEK293/ABCB1 and HEK293/pcDNA3.1 cells: HEK293/ABCB1 cells
were resistant to doxorubicin and YM-155 but not to cisplatin compared to
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HEK293/pcDNA3.1 cells, and collaterally sensitive to compound MX106-4C with a fold
resistance as low as 0.01 was shown in HEK293/ABCB1 cells. This suggested that ABCB1
is a major factor contributing to the selective toxicity of MX106-4C in ABCB1
overexpressing MDR cells.

Resistance to chemotherapy mediated by ABCB1 in colon cancer can be intrinsic due to
endogenous ABCB1 expression. To determine whether compound MX106-4C has a high
inhibitory effect on non-selected ABCB1 positive colon cancer cells, the HCT-15 cell line,
which is known to have intrinsic overexpression of ABCB1, was tested. The result showed
that, compared to SW620 cells with low ABCB1 expression, HCT-15 cells were
hypersensitive to MX106-4C, with an IC50 value as low as 0.167 ± 0.018 µM (Figure 3),
indicating that MX106-4C could be useful not only in treating drug-induced ABCB1
positive colon cancer, but also in combating colon cancer that intrinsically expressed
ABCB1.

28

Table 2. Selective toxicity of compound MX106-4C against ABCB1 overexpressing
cell lines and the parental cell lines.
IC50 ± SDa (µM)

Fold

Treatment

a

KB-3-1

KB-C2

Resistanceb

MX106-4C

4.3267 ± 0.9471

0.3777 ± 0.0582

0.09

YM-155

0.0049 ± 0.0005

37.2953 ± 3.9711

7549.38

doxorubicin

0.0366 ± 0.0070

1.6902 ± 0.4412

46.18

cisplatin

1.1479 ± 0.1292

1.7318 ± 0.1113

1.50

SW620

SW620/Ad300

MX106-4C

0.6755 ± 0.2027

0.0664± 0.0462

0.10

YM-155

0.0039 ± 0.0007

23.3681 ± 2.3697

5931.42

doxorubicin

0.1032 ± 0.0164

15.2409 ± 1.8908

147.68

cisplatin

1.7948 ± 0.0571

5.1210 ± 0.6467

2.85

HEK293/pcDNA3.1

HEK293/ABCB1

MX106-4C

0.2426 + 0.0579

0.0033 ± 0.0006

0.01

YM-155

0.0034 ± 0.0014

47.0512 ± 6.5968

13978.47

doxorubicin

0.0742 ± 0.0106

0.2655 ± 0.0432

3.58

cisplatin

2.2929 ± 0.4799

2.3310 ± 0.4873

1.02

IC50: concentration that reduces cell viability by 50% (mean ± SD). Values in the table

are determined from at least three independent experiments conducted in triplicate.
b

Resistance Fold represents the IC50 value of the drug from ABCB1 overexpressing cells

divided by that from parental cells.
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Figure 3. Cytotoxicity of compound MX106-4C on colon cancer cells.
The IC50 values of MX106-4C for SW620, SW620/Ad300, and HCT-15 cells were
determined by MTT assay. Columns and error bars represented mean ± SD of IC50 values
acquired from three independent experiments in triplicate.
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3.2

Intracellular Accumulation of Compound MX106-4C in ABCB1 Positive

Colon Cancer Cells
To investigate whether the selective toxicity of compound MX106-4C is contributed by
elevated MX106-4C concentration in ABCB1 overexpressing cells, the intracellular
accumulation of compound MX106-4C was determined and compared between SW620
and SW620/Ad300 cells. As shown in Figure 4, the amount of MX106-4C in cells
remained at a comparable level with 2 h and 4 h exposure. The intracellular accumulation
of MX106-4C in SW620 cells was slightly higher than that in SW620/Ad300 cells but the
difference was statistically insignificant, indicating that ABCB1 expression did not affect
the intracellular level of compound MX106-4C. The higher toxicity of MX106-4C in
ABCB1 overexpressing SW620/Ad300 cells was not likely to be associated with uptake or
efflux of the compound.
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Figure 4. Intracellular Accumulation of Compound MX106-4C in SW620 and
SW620/Ad300 Cells.
LC-MS/MS detection of intracellular accumulation of MX106-4C in SW620 and
SW620/Ad300 cells after 2 h and 4 h exposure to 1 µM MX106-4C. Data were normalized
by the protein content of each sample. Columns and error bars represented average values
with SD of three measurements.
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3.3

Interaction of Compound MX106-4C and ABCB1 in Colon Cancer Cells

3.3.1 Effect of Compound MX106-4C on the Function of ABCB1
The effect of compound MX106-4C on the function of ABCB1 was investigated by
ABCB1 ATPase assay and [3H]-paclitaxel accumulation and efflux assay. Unlike
paclitaxel, which is an ABCB1 substrate that can stimulate ABCB1 ATPase activity,
compound MX106-4C at up to 10 µM did not have a significant effect on ABCB1 ATPase
activity (Figure 5), confirming that MX106-4C is not likely to be a substrate of ABCB1.
Furthermore, this result suggested that the collateral sensitivity of MX106-4C was not
through disturbing the ATP hydrolysis function of ABCB1. Consistent with the
observation that MX106-4C neither inhibited nor stimulated ABCB1 ATPase, MX106-4C
did not have significant effects on the efflux function of ABCB1. After exposure to 50 nM
of MX106-4C for 72 h, the intracellular [3H]-paclitaxel level remained at approximately
the same level as the corresponding control group for SW620 and SW620/Ad300 cells,
respectively (Figure 6A). The low retention of [3H]-paclitaxel due to ABCB1 exporting
activity in SW620/Ad300 cells was not significantly affected by MX106-4C (Figure 6B).
On the contrary, the ABCB1 inhibitor tariquidar, at the same concentration of 50 nM, could
significantly increase the intracellular accumulation and then decelerate the efflux of [3H]paclitaxel in SW620/Ad300 cells. The [3H]-paclitaxel accumulation in SW620 cells was
also elevated by tariquidar to a small extent, possibly because of the inhibition of the
endogenous expression of ABCB1 in SW620 cells. As indicated by the negative results
observed from the MX106-4C-treated group compared to the tariquidar-treated group,
compound MX106-4C may not be a functional inhibitor of ABCB1.
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Figure 5. Effect of compound MX106-4C on vanadate (Vi)-sensitive ABCB1 ATPase
activity.
The effect of compound MX106-4C (0-10 µM) on ABCB1 ATPase activity was depicted
as changes in the percentage of basal ATPase activity as concentration changed. Paclitaxel,
as an ABCB1 substrate that can stimulate ABCB1 ATPase activity, was used as a positive
control. Data points and error bars represented the average value and SD obtained from
three independent experiments.
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Figure 6. Effect of compound MX106-4C on intracellular accumulation and efflux of
[3H]-paclitaxel.
(A) The intracellular accumulation of [3H]-paclitaxel in SW620, and SW620/Ad300 after
72 h exposure of vehicle control, 50 nM MX106-4C or 50 nM tariquidar. * p < 0.05
compared to control group. (B) The [3H]-paclitaxel efflux activities of SW620 and
SW620/Ad300 after 72 h exposure of vehicle control, 50 nM MX106-4C or 50 nM
tariquidar. Data represented the mean ± SD of three independent experiments.
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3.3.2 Effect of Compound MX106-4C on the Subcellular Localization of ABCB1
Since the function of ABCB1 was not affected by compound MX106-4C, the selective
toxicity may be related to the change of subcellular localization or expression of ABCB1.
Therefore, the immunofluorescence assay was performed to investigate the effect of
compound MX106-4C on the distribution of ABCB1 expression in cells. As illustrated in
Figure 7, the overexpression of ABCB1 on the plasma membrane in SW620/Ad300 cells
was confirmed by the higher green fluorescence intensity compared to the parental SW620
cells. For 72 h exposure to 50 nM of MX106-4C, the subcellular localization of ABCB1
was not significantly altered, which remained majorly on the cell membrane. A higher
concentration of MX106-4C at 100 nM exerted more observable toxicity to SW620/Ad300
cells as indicated by the cell swelling phenomenon, however, the ABCB1 expression
(fluorescence intensity) and subcellular localization did not show obvious change
compared to the low concentration group and control group.
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Figure 7. Effect of compound MX106-4C on the subcellular localization of ABCB1 in
SW620/Ad300 cells determined by immunofluorescence staining.
ABCB1 and DAPI fluorescence micrographs were combined to create a merged image.
ABCB1 expression was shown in green and cell nuclei were stained blue by DAPI. The
parental SW620 cells were used to compare and confirm the ABCB1 overexpression in
SW620/Ad300 cells. Scale bar represented 20 µm.

37

3.3.3 Effect of Compound MX106-4C on the Expression Level of ABCB1
To further investigate whether compound MX106-4C affects the expression of ABCB1 in
colon cancer cells at the transcriptional level as well as protein level, RT-qPCR and
Western blotting were carried out with drug-selected ABCB1 positive SW620/Ad300 cells
and intrinsically ABCB1 positive HCT-15 cells. As demonstrated in Figure 8A, from 24 h
to 72 h, MX106-4C at 100 nM significantly downregulated ABCB1 mRNA level in
SW620/Ad300 cells to a level comparable to the parental SW620 cells. A similar result
was observed from and HCT-15 cells. The down-regulating effect of MX106-4C on
ABCB1 mRNA level was time-dependent in HCT-15 cells (Figure 8B), whereas this timedependent pattern was not obvious in SW620/Ad300 cells. Albeit a significant reduction
in ABCB1 mRNA level was induced by MX106-4C, the protein expression of ABCB1 was
almost unchanged in MX106-4C-treated SW620/Ad300 and HCT-15 cells (Figure 8 C, D).
Considering that change in protein expression level may require a longer time to be
observable after transcriptional alternation, the ABCB1 protein level was determined in
SW620/Ad300 and HCT-15 cells after extended exposure to compound MX106-4C for up
to 14 days. After long-term treatment, the ABCB1 protein expression was significantly
downregulated in SW620/Ad300 and HCT-15 cells (Figure 9). As the transcriptional
activity but not the function and expression of ABCB1 was not affected by MX106-4C in
short-term exposure, and change in ABCB1 protein expression required prolonged
exposure, MX106-4C may have an indirect regulatory effect on ABCB1 instead of direct
interaction.
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Figure 8. Effect of short term (0-72 h) exposure to MX106-4C on the expression of
ABCB1 in colon cancer cells.
(A) (B) The mRNA expression levels of the ABCB1 gene are normalized by the expression
of the GAPDH gene. Relative mRNA expression was presented as fold change versus
SW620 (A) or HCT-15 control (B). * p < 0.05 compared to SW620/Ad300 control group
(A) or compared to HCT-15 control group (B). (C) (D) Western blotting results of ABCB1
protein expression level change after short-term exposure to 100 nM MX106-4C. GAPDH
was used as a loading control. Relative ABCB1 protein expression was presented as fold
change versus SW620/Ad300 control (C) or HCT-15 control (D). Columns and error bars
represented mean values and SD obtained from three independent measurements.
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Figure 9. Effect of long-term (14 days) exposure to MX106-4C on the expression of
ABCB1 in colon cancer cells.
Western blotting results of ABCB1 protein expression level change after 14-day exposure
to 100 nM MX106-4C. Protein extraction was done at the end of the 14-day incubation.
GAPDH was used as a loading control. Relative ABCB1 protein expression was presented
as fold change versus HCT-15 control. Columns and error bars represented mean values
and standard deviation obtained from three independent measurements.
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3.3.4 Association between ABCB1 Expression and the Selective Toxicity of Compound
MX106-4C
In order to verify the role of ABCB1 expression in MX106-4C-induced selective toxicity,
the ABCB1 gene knockout sublines of SW620/Ad300 and HCT-15 cell lines were
established and tested. The knockout of the ABCB1 gene in SW620/Ad300 and HCT-15
cells was verified by the ABCB1 protein expression detected using Western blotting
(Figure 10A) and by ABCB1 mRNA expression determined using RT-qPCR (Figure 10 B,
C). MTT cytotoxicity test showed that ABCB1 gene knockout re-sensitized SW620/Ad300
and HCT-15 cells to ABCB1 substrate drug doxorubicin (Figure 11B), while the response
to non-substrate drug cisplatin was unaffected (Figure 11C), which confirmed the loss of
ABCB1 in the knockout cell lines. Significantly reduced sensitivity of SW620/Ad300 and
HCT-15 cells to MX106-4C (Figure 11A) was observed. The SW620/Ad300-ABCB1ko
cells were even more unresponsive to MX106-4C compared to SW620 cells, possibly due
to the endogenous ABCB1 expression in SW620 as confirmed in Figure 10B. These results
inferred that the collateral sensitivity effect induced by MX106-4C is ABCB1 expressiondependent.
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Figure 10. Confirmation of ABCB1 knockout in SW620/Ad300 and HCT-15 cells.
(A) Western blotting results of ABCB1 protein expression level in cells. GAPDH was used
as a loading control. (B) (C) The mRNA expression levels of the ABCB1 gene measured
by RT-qPCR normalized by the expression of the GAPDH gene. (B) Relative mRNA
expression was presented as fold change versus SW620. * p < 0.05 compared to SW620.
# p < 0.05 compared to SW620/Ad300. (C) Relative mRNA expression was presented as
fold change versus HCT-15. * p < 0.05. Columns and error bars represented mean values
and SD obtained from three independent measurements.
42

Figure 11. Effects of ABCB1 gene knockout on drug sensitivity of colon cancer cells.
The IC50 values of (A) MX106-4C, (B) doxorubicin, and (C) cisplatin in SW620/Ad300
and HCT-15 cells were determined by MTT assay. Columns and error bars represented
mean ± SD of IC50 values acquired from three independent experiments in triplicate. * p
< 0.05, ** p < 0.01, *** p<0.001.
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3.3.5 Contribution of ABCB1 Efflux and ATP Hydrolysis Function to the Selective Toxicity
of Compound MX106-4C
As the dependence of MX106-4C selective toxicity on ABCB1 expression has been
suggested, whether this selective toxicity requires functional ABCB1 was investigated.
Tariquidar, a third-generation ABCB1 inhibitor, was used to inhibit the ABCB1 efflux
function in cytotoxicity tests with MX106-4C. In order to exclude the possible direct toxic
effect from tariquidar, the selected concentration 1 µM for tariquidar had been confirmed
to be non-toxic and effective in inhibiting ABCB1 function in preliminary tests before
reversal study was performed. As expected, inhibition of ABCB1 using tariquidar resulted
in an effective reverse of doxorubicin resistance in SW620/Ad300 cells (Figure 12B) and
HCT-15 cells (Figure 12 E), while the IC50 values of cisplatin remained approximately the
same (Figure 12 C, F). With ABCB1 function blocked by tariquidar, SW620,
SW620/Ad300, and HCT-15 cells became significantly less sensitive to MX106-4C
(Figure 12 A, D), suggesting that functional ABCB1 was necessary for compound MX1064C to induce selective toxicity.

The roles of ABCB1 efflux function and ATP hydrolysis function in selective toxicity of
MX106-4C were further examined respectively using HeLa S3 cells expressing wild-type
(WT) ABCB1, TM6,12-14A mutant ABCB1 with impaired efflux and acquired uptake
function, and TM6,12-14A-EQ mutant ABCB1 with deficient ATPase function. The
untransduced HeLa S3 cells without ABCB1 expression were used as a control. The results
showed that the TM6,12-14A mutant was less sensitive to MX106-4C compared to cells
with WT ABCB1, whereas the TM6,12-14A-EQ mutant was even more irresponsive with
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an IC50 value comparable to the untransduced cells (Figure 13 A, B). This suggested that
the hypersensitivity to compound 4C is dependent on the drug efflux activity of ABCB and
is more critically dependent on the ATPase activity of ABCB1.
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Figure 12. Reversal effects of tariquidar on drug sensitivities of colon cancer cells.
The MTT assay-determined IC50 values of (A) (D) MX106-4C, (B) (E) doxorubicin, (C)
(F) cisplatin in SW620, SW620/Ad300, and HCT-15 cells with or without the presence of
1 µM tariquidar. Columns and error bars represented mean ± SD of IC50 values acquired
from three independent experiments in triplicate. * p < 0.05, ** p < 0.01.
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Figure 13. Cytotoxicity of compound MX106-4C compound in untransduced HeLa
S3 cells and HeLa S3 cells expressing wild-type (WT), TM6,12-14A, or TM6,12-14AEQ mutant ABCB1.
This result was provided by Drs. Suresh V. Ambudkar and Hadiar Rahman in National
Cancer Institute. (A) The cell viability changes in response to 48-h exposure to various
concentrations of MX106-4C were determined by Cell Titer-Glo viability assay.
Untransduced cells (UN) were used as a control. Data points with error bars displayed the
average viability (%) ± SD obtained from at least three independent experiments performed
in triplicate. (B) The IC50 values (mean with SD) of MX106-4C were obtained from Hela
cells with different ABCB1expression. * p<0.05 compared to WT, # p<0.05 compared to
UN.
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3.4

Effect of Compound MX106-4C on Cell Apoptosis and Cell Cycle in ABCB1

Positive Colon Cancer Cells
As a survivin inhibitor, compound MX106-4C may affect cell apoptosis or cause cell cycle
arrest by inhibiting survivin. To investigate whether the selective toxicity of compound
MX106-4C is correlated to survivin inhibition, the cell apoptosis and cell cycle were
assessed in MX106-4C-treated colon cancer cells. In addition, the effect of MX106-4C on
survivin expression and the downstream effector caspases-3/7 in colon cancer cells was
determined.

3.4.1 Effect of Compound MX106-4C on Cell Apoptosis
As shown in Figure 14, compound MX106-4C increased the rate of apoptosis in ABCB1
overexpressing SW620/Ad300 cells in a concentration-dependent manner; however, this
effect was abolished by knocking out the ABCB1 gene from SW620/Ad300 cells. There
was also a decrease in the percentage of the viable cells with the treatment of compound
MX106-4C in SW620 cells compared to the control group, but not as severe as in
SW620/Ad300 cells. These results revealed that MX106-4C selectively induced apoptosis
in ABCB1 positive colon cancer cells in dependence on the ABCB1 expression level.
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Figure 14. Effect of MX106-4C on cell apoptosis in SW620, SW620/Ad300, and
SW620/Ad300-ABCB1ko cells.
(A) Representative scatter plots of PI (y-axis) vs FITC-annexin V (x-axis). Cells were
classified as viable cells (Annexin V−, PI−), early apoptotic cells (Annexin V+, PI−), late
apoptotic/necrotic cells (Annexin V+, PI+), and damaged cells (Annexin V−, PI+). (B) The
bar graph represented the percentage of viable, early apoptotic, and late apoptotic/necrotic
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cells, respectively. Columns and error bars represent the average cell population (%) and
the SD obtained from three independent experiments. * p<0.05 and ** p<0.01 compared
to the control group.
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3.4.2 Effect of Compound MX106-4C on Cell Cycle
On treatment with 50 nM and 100 nM of compound MX106-4C for different exposure time
lengths, a significant decrease in the percentage of cells at the G2/M phase was observed
in ABCB1 overexpressing SW620/Ad300 cells compared to the control group (Figure 15).
It was also shown that compound MX106-4C induced G0/G1 phase arrests in
SW620/Ad300 cells at 50 nM 48 h and 100 nM 72 h. Interestingly, opposite effects were
observed in MX106-4C-treated SW620 cells compared to the MDR cells. Accumulation at
the G2/M phase and decreased population at G0/G1 phase were found in SW620 cells after
exposure to MX106-4C. In addition, when comparing the control groups, SW620 cells had
more cell population at the G2/M phase and less cell population at G0/G1 phase than
SW620/Ad300 cells, while SW620/Ad300-ABCB1ko cells appeared to be more resemble
that of SW620/Ad300 cells. This indicated that there may be differential expressed genes
between SW620 and SW620/Ad300 cells related to cell cycle regulation, and those are not
regulated by ABCB1 so the SW620/Ad300-ABCB1ko cells remain in the same cell cycle
phase distribution pattern.
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Figure 15. Effect of MX106-4C on cell cycle in SW620, SW620/Ad300, and
SW620/Ad300-ABCB1ko cells.
(A) Representative histograms of the cell population (y-axis) in respect to PI fluorescent
intensity (x-axis). (B) The bar graph represented the percentage of cell population at
G0/G1, S, and G2/M phases, respectively. Columns and error bars represent the average
cell population (%) and the SD obtained from three independent experiments. * p<0.05
compared to the control group.
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3.4.3 Effect of Compound MX106-4C on Survivin Expression
To further investigate whether the cell cycle arrest and apoptosis induced by compound
MX106-4C is correlated to repression on survivin expression in colon cancer cells, the
transcriptional level, as well as protein level of survivin in MX106-4C-treated colon cancer
cells, were determined. As demonstrated in Figure 16, MX106-4C did not alter the mRNA
level of survivin (Figure 16A) but could slightly downregulate survivin protein expression
after 72 h treatment (Figure 16B). As the down regulation of protein expression is not
significant, compound MX106-4C may have an inhibitory effect on survivin rather than an
influence on the expression level.
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Figure 16. Effect of compound MX106-4C on the expression level of survivin in
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells.
(A) The mRNA expression levels of survivin (BIRC5 gene) in SW620, SW620/Ad300, and
SW620/Ad300-ABCB1ko cells after 72-h treatment with 50 or 100 nM MX106-4C.
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Relative mRNA expression was presented as fold change versus SW620 control (ctrl)
group after normalized by the expression of the GAPDH gene. (B) Western blotting results
of survivin protein expression level change after short-term exposure to 100 nM MX1064C. β-actin was used as a loading control. Relative survivin protein expression was
presented as fold change versus SW620 control. Columns and error bars represented
average values and standard deviation obtained from three independent measurements.
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3.4.4 Effect of Compound MX106-4C on Activating Caspases-3/7
As compound MX106-4C has been shown to selectively induce apoptosis in ABCB1
positive colon cancer cells, the caspases-3/7 activation as a possible survivin-regulated cell
apoptosis mechanism was verified by flow cytometry. The result showed that compound
MX106-4C may increase cleaved caspases-3/7 in ABCB1 overexpressing SW620/Ad300
cells but not in parental SW620 cells or ABCB1 deficient SW620/Ad300-ABCB1ko cells
(Figure 17). In addition, the combination of compound MX106-4C with ABCB1 inhibitor
tariquidar significantly reduced the activation of caspases-3/7 in SW620/Ad300 cells,
while the active caspases-3/7 levels in SW620 cells and SW620/Ad300-ABCB1ko cells
were unaffected, suggesting that the cell apoptosis caused by MX106-4C in SW620/Ad300
cells may be through activation of caspases-3/7, which could be an ABCB1-dependent
event.
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Figure 17. The ABCB1-dependent effect of compound MX106-4C on activating
caspases-3/7 in ABCB1 overexpressing SW620/Ad300 cells.
The bar graph represented the percentage of cell population with active caspases-3/7
detections. Columns and error bars represent the average cell population (%) and the SD
obtained from three independent experiments. * p<0.05.
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3.5

Oxidative Stress Induced by Compound MX106-4C in Colon Cancer Cells

3.5.1 Effect of Compound MX106-4C on Intracellular ROS and GSH Levels
As ROS production and oxidative stress have been considered as a mechanism for CS
effects, the intracellular ROS levels and GSH levels were detected in colon cancer cells
treated with MX106-4C. Increased intracellular ROS levels and reduced GSH levels were
observed in ABCB1 overexpressing SW620/Ad300 cells treated with compound MX1064C, following a time-dependent manner but not concentration-dependent manner (Figure
18A, C). In SW620/Ad300 cells, the intracellular GSH level reduced by MX106-4C could
be replenished by the addition of 5 mM NAC, a precursor of GSH acting as ROS scavenger,
but the elevated intracellular ROS levels by MX106-4C were partially revered. These
phenomena were only presented in ABCB1 overexpressing SW620/Ad300 cells but not
the parental SW620 or ABCB1 deficient SW620/Ad300-ABCB1ko cells (Figure 18 A, B,
D), indicating that compound MX106-4C can selectively lead to oxidative stress in ABCB1
overexpressing cells, which could be partially mitigated by the addition of antioxidant
NAC.
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Figure 18. Oxidative stress in SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko
cell lines upon treatment with MX106-4C.
(A) Scatter graph of relative intracellular ROS levels. # p<0.05 compared to the control
group of the corresponding cell line. * p<0.05 compared to the same treatment of the
parental SW620 cell line. (B)-(D) The relative intracellular GSH levels in SW620 (B),
SW620/Ad300 (C), and SW620/Ad300-ABCB1ko (D) cells, respectively. * p<0.05
compared to the control group. Relative intracellular ROS levels and relative intracellular
GSH levels were calculated by normalizing the ROS (fluorescence intensity) and GSH
detection (quantified nmole GSH according to standard curve) data using the protein
content of each sample. The average values and SD obtained from three independent
experiments were presented.
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3.5.2 Role of Oxidative Stress in Cell Apoptosis Induced by MX106-4C
Given that compound MX106-4C could induce oxidative stress on ABCB1 overexpressing
cells, which could be mitigated by antioxidant NAC, the ability of NAC to counteract
MX106-4C-induced cytotoxicity and cell apoptosis was then evaluated. The result showed
that NAC cannot alleviate the cytotoxicity of compound MX106-4C on ABCB1
overexpressing SW620/Ad300 cells (Figure 19 A). In addition, the combination of
compound MX106-4C and NAC have no significant difference in cell apoptosis compared
to MX106-4C alone (Figure 19 B), suggesting that compound MX106-4C-mediated
oxidative stress may not be the main mechanism of the CS effect.
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Figure 19. Effect of NAC on MX106-4C induced cytotoxicity and apoptosis in SW620,
SW620/Ad300, and SW620/Ad300-ABCB1ko cells.
(A) The IC50 values of compound MX106-4C with or without the presence of NAC
determined by MTT assay. Columns and error bars represented average values and
standard deviation obtained from three independent measurements in triplicate. (B)
Representative scatter plots of PI (y-axis) vs FITC-annexin V (x-axis).
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3.6

Analysis of Transcriptionally Dysregulated Gene Expressions Induced by

MX106-4C in ABCB1 Overexpressing Colon Cancer Cells
From mRNA-sequencing analysis, differentially expressed genes (DEGs) with statistical
significance were selected with p < 0.05, adjusted p value (padj) < 0.05 and fold change >
2 or <0.5. Following this criterion, 3079 DEGs were found when comparing
SW620/Ad300 control and SW620 control groups, in which 1389 were upregulated and
1699 were downregulated (Figure 20A). In the SW620 MX106-4C group, 337 genes were
significantly differentially expressed compared to the SW620 control group, with 107
upregulated and 230 downregulated (Figure 20C). On the contrary, in SW620/Ad300
MX106-4C group, most DEGs were upregulated when comparing to SW620/Ad300
control group, with 721 upregulated and 98 downregulated (Figure 20B). Similarly, 2008
genes were differentially expressed in SW620/Ad300 MX106-4C group compared to the
SW620 MX106-4C group, mostly (1704 out of 2008) were upregulated (Figure 20D). The
DEG with the largest fold change is ABCB1, which showed approximately 123.7-fold
upregulated in SW620/Ad300 control group compared to the SW620 control group. This
confirmed that the tested samples were reliably reflecting the ABCB1 expression
difference between parental and resistant cells. The significant DEGs were subjected to
heat map graphing for comparison among four groups. The heat map of DEGs revealed
that most genes that were upregulated by MX106-4C treatment in SW620/Ad300 cells did
not change in the same trend in SW620 cells (Figure 20E). This difference might be
contributed by the stronger stress induction induced by MX106-4C in ABCB1
overexpressing SW620/Ad300 cells, or by the altered gene expression profile of
SW620/Ad300 cells compared to the parental SW620 cells.
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KEGG pathway analysis for DEGs was used to elucidate the pathways related to the gene
regulation induced by MX106-4C. The DEGs between SW620/Ad300 MX106-4C group
and SW620/Ad300 control group were enriched in 28 pathways with p < 0.05 (Figure 21A),
however, none of these enriched pathways had a padj value <0.05. On the other hand, both
DEG lists from SW620/Ad300 vs SW620 and SW620 MX106-4C vs SW620 control got
only one significantly enriched pathway in the category of KEGG, which is the p53
signaling pathway (Figure 21 B, C). The p53 pathway is closely associated with cell
apoptosis and cell cycle regulation. Therefore, dysregulation of the p53 pathway induced
by MX106-4C may be an important mechanism accounting for the selective toxicity of
MX106-4C. The DEGs that are involved in the p53 pathway were then summarized in
Table 3. The trend of expression level changes for the listed gene was validated using RTqPCR and further tested in SW620/Ad300-ABCB1ko cells to confirm whether the
dysregulation of expression induced by MX106-4C is ABCB1-dependent.

RT-qPCR validation tests results showed that TP53 mRNA levels were comparable among
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells (Figure 22A). The
downstream GADD45A gene expression was low in SW620/Ad300 compared to parental
SW620 and SW620/Ad300-ABCB1ko cells, however, the down regulating trend upon
treatment with MX106-4C was similar among three cell lines (Figure 22G), which is
consistent with the sequencing data. Another downstream molecule of p53, GADD45B,
was shown slightly upregulated at mRNA level in SW620/Ad300 cells, which was
downregulated as SW620/Ad300 cells were exposed to MX106-4C (Figure 22 H). Since
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this was inconsistent with the mRNA-sequencing result, and the change was insignificant,
it was considered that GADD45B mRNA expression may not be affected significantly by
MX106-4C. As TP53 appeared to be unaffected, whereas the regulation on GADD45A was
ABCB1-independent, p53 and the downstream GADD45A and GADD45B may not be
majorly involving factors in the MX106-4C-induced CS effect. CNKN1A (p21) was
upregulated, and CDK4, as well as CDK6, were downregulated specifically in
SW620/Ad300 cells (Figure 22 B, C, D), which were consistent with the sequencing data.
The cell cycle arrest at G0/G1 induced by compound MX106-4C may be explained by the
dysregulation on p21-CDK4/CDK6 pathway via a mechanism independent of p53.
Unexpectedly, the encoding gene for cyclin D1, CCND1, showed a high basal expression
in SW620/Ad300-ABCB1ko cells, which was significantly reduced by MX106-4C (Figure
22E). As the cell cycle was not shown to be disturbed by MX106-4C in SW620/Ad300ABCB1ko cells, further protein level determination is required to investigate this
inconsistency. Similar to what was found from mRNA-sequencing data, FAS gene
expression was low in SW620/Ad300 cells and was approximately 2-fold upregulated upon
exposure to MX106-4C, while the changes in SW620 and SW620-ABCB1ko cells were
not obvious (Figure 22F). Thus, upregulation of FAS might be involved in MX106-4C
apoptosis in SW620/Ad300 cells. However, the transcriptional level may not necessarily
reflect the protein expression level, therefore, further validation with protein expression is
required.
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Figure 20. Differentially expressed genes (DEGs) profile by mRNA-sequencing.
(A)-(D) The volcano scatter plots presented differentially expressed genes between
different compared groups: SW620/Ad300 control vs SW620 control (A), SW620 MX1064C 100 nM 72h vs SW620/Ad300 control (B), SW620 MX106-4C 100 nM 72 h vs SW620
control (C), and SW620 MX106-4C 100 nM 72h vs SW620 control (D). padj is the adjusted
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p value. Log2(Fold Change) at -1 and 1, -Log10(padj) at 1.3 were labeled by the dotted
lines. Differentially expressed genes with fold change >2 or <-2, i.e. Log2(Fold Change)>1
or < -1, and padj<0.05, i.e. -Log10(padj) >1.3, were selected as significant DEGs for
heatmap graphing. (E) Heatmap showed significantly DEGs. Heatmap is generated based
on the fragments per kilobase of transcript per million mapped reads (FPKM) of each gene,
which represent the relative expression of the transcript. Z score = (FPKM- row mean
FPKM)/SD.
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Figure 21. KEGG pathway enrichment analysis of DEGs from mRNA-sequencing
analysis.
KEGG pathway enrichment analysis of DEGs from (A) SW620/Ad300 MX106-4C 100
nM 72 h vs SW620/Ad300 control comparison, (B) SW620 MX106-4C 100 nM 72 h vs
SW620 control comparison, and (C) SW620/Ad300 control vs SW620 control comparison.
The enriched pathways with p<0.05 were shown. An adjusted p value (padj) was obtained
by the Bonferroni Šidák method as the false discovery rate. The fold enrichment is the ratio
of (number of input genes involved in this pathway/number of all input genes)/(number of
genes within this KEGG term on the background list/number of genes on the background
list ). * padj<0.05.
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Table 3. DEGs from mRNA-sequencing analysis that are involved in the p53 pathway.
SW620/Ad300

SW620/Ad300

SW620

SW620/Ad300

MX106-4C vs control

control

MX106-4C vs control

MX106-4C

Gene
vs SW620 control

vs SW620 MX106-4C

Name
log2Fold

padja

Change
p53

log2Fold

padj

Change

log2Fold

padj

Change

log2Fold

padj

Change

0.2716

0.0003

0.1816

0.0157

0.3084

2.21E-06

0.1748

0.0104

2.6850

6.78E-37

-3.0099

1.16E-49

-

>0.05

-

>0.05

CDK4

-0.5485

8.69E-09

0.4673

8.42E-07

0.1979

0.0484

-0.2584

0.0061

CDK6

-0.4985

6.27E-16

0.4854

1.32E-15

0.1974

0.0008

-0.1842

0.0018

Cyclin D1

0.4918

3.45E-16

0.3396

8.65E-07

0.1458

0.0433

0.7166

1.36E-41

0.4966

2.21E-08

-1.8817

0.0000

-1.2769

1.96E-

-

>0.05

(TP53)
p21
(CDKN1A)

(CCND1)
GADD45A
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a

GADD45B

1.3964

8.66E-25

-1.3492

0.0000

-1.5209

1.83E-29

1.6695

4.55E-33

FAS

1.0069

0.0023

-1.0255

0.0127

-

>0.05

-

>0.05

padj: The p values for DEGs were calculated by quasi-likelihood F-test (QLF). Then

Benjamini-Hochberg procedure was used to adjust the p value giving padj as a false
discovery rate.
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Figure 22. Validation of mRNA-sequencing data by RT-qPCR.
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were treated with vehicle
control, 50 and 100 nM of MX106-4C, respectively for 72 h. The mRNA expression levels
were determined using RT-qPCR. Relative mRNA expression was presented as fold
change versus SW620 control group after normalized by the expression of the GAPDH
gene. Columns and error bars represented average values and standard deviation obtained
from at least three independent measurements. * p<0.05.
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3.7

Analysis of Dysregulated Protein Expression Induced by MX106-4C in

ABCB1 Overexpressing Colon Cancer Cells
Reverse phase protein array (RPPA) was performed to analyze the dysregulated protein
expression induced by MX106-4C in ABCB1 overexpressing colon cancer cells, and to
identify the potential mechanism of action. A heatmap was used to compare the
differentially expressed protein in different groups. Similar to what was observed from
mRNA-sequencing data, the differentially expressed proteins in SW620/Ad300 MX1064C group compared to SW620/Ad300 control mostly had an opposite regulatory pattern to
the change induced by MX106-4C in SW620 cells. From the heatmap, it can be observed
that proteins that were upregulated upon MX106-4C treatment in SW620/Ad300 cells were
mostly unaffected or downregulated upon MX106-4C treatment in SW620 cells (Figure
23). The different gene expression profiles between SW620/Ad300 cells and parental
SW620 cells may play an important role in causing the differential response to MX106-4C.
Besides, cleaved caspase-3, which is the active form of caspase-3 that mediates cell
apoptosis, was shown to be selectively increased in MX106-4C-treated SW620/Ad300
cells. This confirmed the previous finding from cell apoptosis assay and caspases-3/7 assay
that MX106-4C could induced cell apoptosis in ABCB1 overexpressing SW620/Ad300
cells via activating caspases-3.

The differentially expressed proteins (padj <0.05 with fold change>2 or <0.5) were further
subjected to KEGG pathway analysis. None of the differentially expressed proteins had
more than 2-fold change when comparing SW620 MX106-4C groups with the control
group, and there are only 12 significantly differentially expressed proteins for
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SW620/Ad300 control vs SW620 control, which is a small list not likely to generate
reliable KEGG enrichment analysis. Therefore, KEGG enrichment analysis was only
performed for SW620/Ad300 MX106-4C groups vs SW620/Ad300 control group (36
entries). The analysis result showed that the p53 pathway was significantly enriched
(Figure 24), which suggested that the p53 pathway may be involved in MX106-4C induced
gene dysregulation at the transcriptional level as well as protein level. The differentially
expressed proteins that are members in the p53 pathway, including all that got p<0.05 with
or without 2-fold change, were then summarized in Table 4. And the trend of expression
level change induced by MX106-4C was validated using Western blotting for the listed
proteins.

As the RPPA only detects 307 cancer-associated proteins and some hits from mRNAsequencing may not be included in the list, to further elucidate the involvement of the p53
pathway in MX106-4C-induced selective toxicity, protein levels of CDK4 and CDK6 were
also detected. The Western blotting validation tests results showed that p53, p21 and pRb
protein levels were not significantly changed among the cell lines and treatment groups.
CDK6 and phospho-pRb proteins were selectively downregulated in ABCB1
overexpressing SW620/Ad300 cells, which was consistent with the RT-qPCR result and
the RPPA report, respectively. CDK4 was also downregulated but the effect was not
specific to ABCB1 overexpressing cells (Figure 25). Therefore, the selectively down
regulation of CDK6 and phospho-pRb may explain the selective induction on cell cycle
arrest and cell apoptosis by MX106-4C in ABCB1 positive colon cancer cells.
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Figure 23. Differentially expressed protein profile by RPPA.
(A) Heatmap showed all proteins detected in RPPA. Differentially expressed proteins with
fold change >2 or <-2, and padj <0.05 in any comparisons were selected as significant data
for secondary heatmap graphing. (B) The secondary heatmap showed significantly
differentially expressed proteins with the name of entry at each row. Heatmap is generated
based on normalized log2 quantified protein expression values (NormLog2). Z score =
NormLog2- row median NormLog2.
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Figure 24. KEGG pathway enrichment analysis of significantly deferentially
expressed proteins from RPPA analysis for SW620/Ad300 MX106-4C 200 nM 72 h vs
SW620/Ad300 control comparison.
The enriched pathways with p<0.05 were shown. An adjusted p value (padj) was obtained
by the Bonferroni Šidák method as the false discovery rate. The fold enrichment is the ratio
of (number of input genes involved in this pathway/number of all input genes)/(number of
genes within this KEGG term on the background list/number of genes on the background
list ). * padj<0.05.
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Table 4. Differentially expressed proteins from RPPA analysis that are involved in
the p53 pathway.
SW620/Ad300
SW620/Ad300

SW620/Ad300

SW620

MX106-4C 200 nM

control

MX106-4C 200 nM

vs control

vs SW620 control

vs control

MX106-4C 200 nM
vs SW620 MX106-

Protein

4C 200 nM

name
log2Fold

log2Fold
padj

Change

2Fold
padj

Change

log2Fold
padj

Change

padj
Change

p53

-1.3831

0.0056

0.0032

0.9759

0.2885

0.1050

-1.6680

0.0050

p21

0.8925

0.0327

-0.3018

0.0803

0.1922

0.1638

0.3986

0.0716

cyclin D1

0.3346

0.0025

-0.0598

0.4321

0.2638

0.0913

0.0110

0.5457

-1.7176

0.0076

-0.4939

0.0181

-0.2423

0.0071

-1.9691

0.0054

1.0268

0.0229

-0.0183

0.8630

0.0032

0.9783

1.0053

0.0129

phosphoryla
ted pRb
(p-pRb
S807/S811)
cleaved
caspase-3
(active form)
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Figure 25. Validation of RPPA data by Western blotting.
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were treated with vehicle
control, 50 and 100 nM of MX106-4C, respectively for 72 h. The protein expression levels
were determined using Western blotting. Relative greyscale values were shown below each
band, which were determined by the greyscale of the band normalized by the greyscale of
the β-actin band on the same PVDF membrane. The greyscale measurements were carried
out in ImageJ.
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3.8

Synergistic Effect of Doxorubicin Co-administrated with MX106-4C on

Inhibiting Colon Cancer Cell Viability
The combined inhibitory effect of doxorubicin co-administrated with MX106-4C on cell
viability was assessed in colon cancer cells, including SW620, SW620/Ad300, and HCT15 cell lines. As the sensitivities to doxorubicin and MX106-4C are different among the
cell lines due to different expression levels of ABCB1, the concentrations of doxorubicin
and MX106-4C were adjusted for each cell line by putting the concentration around IC50
of single-drug treatment as the median. As shown in Figure 26A, in SW620 cells, the
combinations with CI values<1 were mostly observed when doxorubicin concentration was
0.03 or 0.1 µM and MX106-4C concentration was 0.3 or 1 µM, while other combinations
had CI values >1 or closed to 1. This suggested that combination effects were
concentration-dependent. On the other hand, in ABCB1 overexpressing SW620/Ad300
and HCT-15 cells, most CI values of the combination were less than 1 except for several
closed to 1 (Figure 26 B, C), indicating that the cytotoxic effects of doxorubicin in
combination with MX106-4C at the tested concentration ranges could have synergistic
effect on SW620/Ad300 and HCT-15 cells. The difference between SW620 and the other
two ABCB1 overexpressing cell lines revealed that MX106-4C may be beneficial to
combat ABCB1-mediated MDR by combination treatment with doxorubicin.
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Figure 26. The synergistic anti-cancer effect from multiple ratios of MX106-4C and
doxorubicin in colon cancer cells.
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Summary tables for (A) SW620, (B)SW620/Ad300, and (C) HCT-15 cell lines showing
potency (% inhibition), combination index (CI), and combination of MX106-4C and
doxorubicin combined at various concentrations and ratios. Combinations exhibiting
synergism (CI<1) were highlighted in the table. Data were the average %inhibition
obtained from three independent experiments in triplicate.
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3.9

Capability of Compound MX106-4C to Re-sensitize ABCB1 Overexpressing

MDR Colon Cancer Cells
As significant down regulation of ABCB1 had been observed after 14-day exposure to
compound MX106-4C, the alteration on drug sensitivities was further examined to evaluate
the capability of compound MX106-4C to re-sensitize MDR colon cancer cells. After 14day exposure to 100 nM MX106-4C, SW620/Ad300, and HCT-15 cells gained
approximately 3-fold more resistance to the untreated cells (Figure 27 A, D). Enhanced
sensitivity to ABCB1 substrate doxorubicin was significant in SW620/Ad300 cells after
14-day treatment with MX106-4C, while HCT-15 cells got less significantly
(approximately 2-fold) re-sensitized to doxorubicin by long term exposure to MX106-4C
(Figure 27 B, D). This was in accord with the difference in ABCB1 protein level in cells
with or without 14-day exposure to MX106-4C as discussed in section 3.3.3. Cisplatin,
which is not transported by ABCB1, was used as a negative control. The IC50 values of
cisplatin stayed at a similar level between treated and untreated groups (Figure 27 C, D).
These results indicated that the low resistance to MX106-4C and re-sensitization to
doxorubicin were associated with the decreased ABCB1 protein expression by long-term
treatment of MX106-4C.
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Figure 27. Effect of 14-day exposure to 100 nM MX106-4C on drug sensitivity profile
of SW620/Ad300 and HCT-15 cells.
(A)-(C) The IC50 values of (A) MX106-4C, (B) doxorubicin, and (C) cisplatin in SW620,
SW620/Ad300, and MX106-4C treated SW620/Ad300 cells for 14 days. (D) The IC50
values of MX106-4C, doxorubicin, and cisplatin in HCT-15 cells with or without 14-day
treatment with MX106-4C. Columns and error bars represented mean ± SD of IC50 values
determined by MTT assay from three independent experiments in triplicate. * p < 0.05.
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3.10

Evaluation on Selective Toxicity of MX106-4C in Colon Cancer Multicellular

Tumor Spheroids (MCTSs)
To further evaluate the selective toxicity of MX106-4C on MDR colon cancer cells in a
tumor structure, the multicellular tumor spheroid (MCTS) model was used to mimic the
natural biology of tumors. It has been reported that MCTSs could have different sensitivity
to chemotherapeutic agents compared to 2D monolayer cultured cells because of the
differential diffusion of drugs in spheroid structure (Han et al., 2021). Therefore, a
preliminary experiment was used to identify the appropriate concentration of MX106-4C
in MCTSs tests. Based on the IC50 values obtained from the MTT assay, three
concentrations (100, 300, 1000 nM) were tested in a preliminary experiment, and 300 nM,
which was neither too toxic nor too ineffective to all spheroids, was selected for further
experiment.

As depicted in Figure 28A, MX106-4C at 300 nM induced significant growth inhibition in
SW620/Ad300 spheroids, whereas the growth of spheroids from SW620 and
SW620/Ad300-ABCB1ko cells was hardly affected. SW620/Ad300 spheroids treated with
MX106-4C had a significantly smaller increase in the diameter of the cell aggregates
compared to the control group (Figure 28B). HCT-15 spheroids treated with MX106-4C
also showed slower growth in diameter compared to the control group, while the growth
HCT-15-ABCB1ko spheroids were not affected by 300 nM MX106-4C (Figure 28C).
Besides of the growth retardation effects, another major observation from HCT-15
spheroid treated with MX106-4C was the less aggressive growth pattern compared to the
control group (Figure 28A). The hypersensitivity to MX106-4C in ABCB1 overexpressing
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spheroids was consistent with the cytotoxicity effects observed from the MTT assay,
suggesting that the selective toxicity of MX106-4C observed from cell-based assays could
be retained in a tumor setting.
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Figure 28. Growth retardation induced by compound MX106-4C in multicellular
tumor spheroids (MCTSs) of colon cancer cell lines.
(A) Representative images of the MCTSs treated with either vehicle control (culture media)
or 300 nM MX106-4C at time points 0, 24, 48, and 72 h. Scale bar represented 200 µm.
(B) (C) Change of MCTSs volumes after treatment. Percentage of MCTSs volume was
calculated by (spheroid volume – spheroid volume at timepoint-0)/spheroid volume at
timepoint-0 × 100%. * p < 0.05 compared to the control group of the corresponding cell
line.
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3.11

Evaluation on Cytotoxicity of MX106-4C on Normal Colon Cells

To evaluate the safety of compound MX106-4C, cytotoxicity tests were performed using
human normal colon fibroblast cells, CCD-18Co. As shown in Figure 29, the inhibitory
effect of MX106-4C on the viability of CCD-18Co cells was less significant compared to
the three colon cancer cell lines tested (Figure 29). The selectivity index (SI = IC50 from
normal cells ÷ IC50 from cancer cells) (Badisa et al., 2009) was calculated to determine
the selectivity of MX106-4C against cancer cells. An SI value higher than 2 suggests
selective toxicity against cancer cells and relative safety in normal cells (Awang et al.,
2014). As demonstrated in Table 4, the SI values of CCD18Co versus SW620/Ad300 was
10.1 and that of CCD18Co versus HCT-15 was 5.7, indicating that the selectivity of
MX106-4C was good against ABCB1 positive colon cancer cells. Since MX106-4C is a
collateral sensitivity agent, the IC50 value of MX106-4C from SW620 cells with low
ABCB1 expression was closer to that from CCD18Co cells, leading to a smaller SI value
of 1.9. This suggested that MX106-4C may be safer to treat ABCB1 positive colon cancers.
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Figure 29. Comparison on the cytotoxicity of compound MX106-4C against colon
cancer cell lines and normal colon cell line.
The cell viability changes in response to various concentrations of MX106-4C were
determined by MTT assay. Data points with error bars displayed the average viability (%)
± SD obtained from at least three independent experiments performed in triplicate.
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Table 5. Cytotoxicity of Compound MX106-4C to Normal Colon Cell Line and
Selectivity against Colon Cancer Cell Lines

a

Cell line

MX106-4C IC50a (nM)

Selectivity index (SI)b

CCD-18Co

551.95 ± 65.03

-

SW620

294.47 ± 58.27

1.9

SW620/Ad300

54.66 ± 4.13

10.1

HCT-15

99.25 ± 15.06

5.7

IC50: concentration that reduces cell viability by 50% (mean ± SD). Values in the table

are determined from at least three independent experiments conducted in triplicate.
b

Selectivity index (SI) = IC50 from normal cells ÷ IC50 from cancer cells
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CHAPTER 4 DISCUSSION
The ABCB1 expression is closely correlated with MDR in colorectal cancer, therefore,
various approaches to suppress ABCB1 have been developed extensively investigated. As
the outcomes for applications of ABCB1 inhibitors in clinical settings have been
disappointing, novel strategies are urgently required for surmounting ABCB1-mediated
cancer MDR, such as to develop novel CS agents that are selectively toxic to ABCB1
overexpressing cancer cells. In this study, the selective toxicity of compound MX106-4C
against ABCB1 positive colon cancer cells was characterized and the mechanism of the
selective toxicity was investigated.

In the cytotoxicity test, the ABCB1 overexpressing MDR cell lines exhibited resistance to
ABCB1 substrate doxorubicin and YM155, while cisplatin, which was used as a nonsubstrate control of ABCB1, had similar cytotoxic effects on both parental and resistant
cell lines. This confirmed the ABCB1-mediated MDR characteristics of the cell models
utilized in the present study. MX106-4C appeared to be a potent CS agent for both
intrinsically ABCB1 positive colon cancer HCT-15 cells and acquired ABCB1
overexpressing colon cancer SW620/Ad300 cells. Sensitivities of cancer cells towards a
chemotherapeutic agent are usually correlated with the intracellular concentration. For
example, ABCB1 substrates like doxorubicin have low efficacy in ABCB1 overexpressing
MDR cancer because of the reduced intracellular accumulation mediated by ABCB1 efflux
activity (Shen et al., 2008). However, the accumulation level of compound MX106-4C was
shown to be comparable in ABCB1 overexpressing SW620/Ad300 cells and the parental
SW620 cells, suggesting that the selective toxicity of MX106-4C was not contributed by
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increased drug accumulation but by enhanced activities of MX106-4C specifically in
ABCB1 positive colon cancer cells. Therefore, MX106-4C is likely to target a biological
molecule that is overexpressed in ABCB1 positive cells or target hyperactive biological
events that are dependent on ABCB1 or other molecules overexpressing simultaneously
with ABCB1.

From the previous reports, the selective toxicities of CS agents are generally ABCB1dependent, which could be abrogated by applying an ABCB1 inhibitor or silencing ABCB1
(Callaghan et al., 2014; Ludwig et al., 2006; Nakagawa-Goto et al., 2010). Depending on
the drug properties, CS agents may interact with ABCB1 directly as a substrate or inhibitor,
respectively resulting in stimulation on ATP hydrolysis and ROS production (Jansson et
al., 2015; Laberge et al., 2009), or inhibiting ABCB1 function thereby disturbing ABCB1dependent events that are involved cell survival (Kuo et al., 2011). Hence, interaction with
ABCB1 was considered as a possible mechanism of action for MX106-4C. Functional
assays measuring ABCB1 mediated drug efflux and ATPase activity were carried out. The
ABCB1 drug efflux activity can be affected by a substrate or an inhibitor with ATPase
stimulating effect or inhibitory effect, respectively (Nandigama et al., 2019). MX106-4C
neither stimulated nor inhibited the ATPase activity of ABCB1, and it did not affect the
ABCB-mediated [3H]-paclitaxel efflux activity, suggesting that it may not be a substrate
or typical inhibitor of ABCB1. Nevertheless, the results that the collateral sensitivity effect
of MX106-4C can be reversed by applying ABCB1 inhibitor tariquidar, ABCB1 knockout,
or ABCB1 dysfunction mutant indicated a dependence relationship between MX106-4Cmediated CS effect and functional ABCB1 expression. Therefore, it is likely that MX106-
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4C did not interact with ABCB1 directly but interacted with downstream molecules or
events that require functional ABCB1.

In particular, it was shown that the TM6,12-14A mutant with impaired efflux function but
normal ATPase function only partially reversed the selective toxicity of MX106-4C,
whereas the TM6,12-14A-EQ mutant with deficient ATPase function completely abolished
the selective toxicity, indicating a critical contribution of ATP hydrolysis in the CS effect
of MX106-4C. The involvement of ABCB1-mediated ATP hydrolysis in CS effects has
been associated with ROS production (Efferth et al., 2020; Pluchino et al., 2012). The
hypothetical mechanism is that when the cells continue to replenish the ATP consumed by
ABCB1 ATPase, ADP passes oxidative phosphorylation thereby generating ROS to
supplement ATP (Karwatsky et al., 2003). As expected according to the finding that the
CS effect of MX106-4C required ABCB1 ATPase activity, it was observed that MX1064C could increase ROS generation in SW620/Ad300 cells but not in parental SW620 cells
or ABCB1 deficient SW620/Ad300-ABCB1ko cells. Although MX106-4C was shown to
have no direct stimulation on ABCB1, the assay using insect cell membranes may not truly
reflect the ABCB1 ATPase in viable cancer cells. Since exporting activity and ATPase
function are suggested as requirement for MX106-4C-induced CS effect, it can be
hypothesized that substrate efflux activity of ABCB1 consuming ATP is ongoing during
the process where MX106-4C exerts toxic effect to cells, thereby generating ROS. The
possibility that MX106-4C causes generation or release of physiological ABCB1 substrate
in cells to indirectly stimulate ABCB1 ATPase cannot be excluded. Further direct
investigation on ATP consumption and ABCB1 ATPase activity is required for
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confirmation. The induced ROS production may be a possible explanation for the
observation of cell swelling from immunofluorescence microscopic images of
SW620/Ad300 cells treated with 100 nM MX106-4C for 72 h, because ROS accumulation
is known to be correlated with mitochondria dysfunction such as calcium overload,
mitochondrial permeability transition, and morphological alteration of mitochondria,
which can lead to oncosis-like cell death (Du et al., 2010; Guo et al., 2013). Nevertheless,
whether mitochondria damage is involved in the selective toxicity of MX106-4C requires
further investigation. Albeit increased ROS production in MX106-4C-treated
SW620/Ad300 cells, this was suggested to be a minor factor in MX106-4C-mediated
selective toxicity, because coadministration of ROS scavenger NAC replenished
intracellular GSH but failed to counteract the cytotoxicity of MX106-4C. The ROS
production may be an accompanied phenomenon of ABCB1 activity, which may act as
synergistic contributor rather than major contributor to the cytotoxicity of MX106-4C.

Additionally, MX106-4C may potentially regulate ABCB1 expression. It was found that
short-term (up to 72 h) exposure to 100 nM MX106-4C downregulated ABCB1 expression
at mRNA level but not protein level, while long-term (14 days) exposure significantly
reduced ABCB1 protein expression. Similar effects have been reported for the other CS
compounds, NSC73306 and KP772, which caused loss of ABCB1 protein expression
respectively in HCT-15 cells after three weeks exposure (Ludwig et al., 2006) and in KBC1 cells after 20 passages selection (Heffeter et al., 2007). However, little was known about
the mechanism for down regulating ABCB1 expression in long term exposure. It could be
possible regulation on gene expression pre-transcriptionally. Another possibility is the
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selection pressure from MX106-4C. In the field of cancer chemotherapy, it has been
suggested that drug resistance can arise through continuous selection for cells that display
higher drug tolerance, which exhibited a higher stability compared to the sensitive cells
and survive upon subsequent cell divisions (Bell & Gilan, 2020). Therefore, the loss of
ABCB1 expression during long-term exposure could also be contributed by survival
advantages of colonies with low ABCB1 expression and further flourishment of such
colonies. Further experiment with monitoring on ABCB1 expression in cells from the
beginning of exposure may help elucidate this question.

Besides interaction with ABCB1, the interaction of MX106-4C with survivin, which is its
designated target, may also contribute to the CS effects. Survivin functions as an inhibitor
of apoptosis mainly by binding and inhibiting the activation of caspases-3 and 7 (Garg et
al., 2016). In addition, survivin plays a regulatory role in cell cycle progression. It has been
reported that overexpression of survivin in human hepatoma cells could interaction with
CDK4, thereby counteracting G1 arrest and accelerate S phase shift (Suzuki et al., 2000).
In order to investigate whether survivin inhibition is involved in the selective toxicity of
MX106-4C, the effects of MX106-4C on cell cycle arrest, cell apoptosis and expression of
survivin were investigated. The result that MX106-4C induced cell apoptosis and cell cycle
arrest at G0/G1 indicated survivin inhibition effect exerted by MX106-4C at 100 nM. The
increased level of the active form of caspases-3/7, which are the effector of survivin, were
observed in MX106-4C-treated SW620/Ad300 cells, further confirming survivin inhibition
in SW620/Ad300 cells. However, unlike MX106 or other analogs that can degrade survivin
(Wang et al., 2018), MX106-4C did not alter the expression of survivin, which suggested
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that the inhibitory effect may be functional inhibition instead of regulation on the survivin
expression. It is also possible that the concentration used is relatively low thus it is not
potent enough to degrade survivin. Interestingly, although the survivin expression levels
were comparable among SW620, SW620/Ad300 and SW620/Ad300-ABCB1ko cells, the
cell cycle arrest at G0/G1 phase and cell apoptosis induced by MX106-4C at 100 nM
selectively occurred in ABCB1 overexpressing SW620/Ad300 cells. Besides, the enhanced
activity of cleaved caspases-3/7 in SW620/Ad300 cells could be attenuated by ABCB1
inhibitor tariquidar. This inferred that the survivin functional inhibition by MX106-4C was
also ABCB1 dependent, by which it may be able to explain why there was mild apoptosis
induction in SW620 cells with low ABCB1 expression compared to the unaffected
SW620/Ad300-ABCB1ko cells. Unexpected increase in cell populations at G2/M phase
was observed in parental SW620 cells treated with MX106-4C. As the ABCB1 knockout
subline of SW620/Ad300 did not have this type of response, the G2/M phase arrest in
SW620 cells induced by MX106-4C is not likely to be correlated with ABCB1 expression.
It may be caused by differential expressions of certain cell cycle modulating molecules
between SW620 and SW620/Ad300 cells occurred during doxorubicin selection.
Nevertheless, the type of cell cycle change appeared to have minimal influence on causing
cell death in SW620 cells.

Further bioinformatics analysis revealed that the p53 pathway may be an important player
in MX106-4C induced cell cycle arrest and apoptosis. Vital molecules involved in this
process may include p21, CDK4, CDK6, and phosphorylated pRb. CDK4/6 are cyclindependent kinases responsible for regulating the cycle progression from the G1 phase to
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the S phase by binding to cyclin D and inactivating phosphorylation of the central tumor
suppressor pRb (Bonelli et al., 2019). The downstream effector pRb protein, as a tumor
suppressor, is responsible for G1 checkpoint by blocking S-phase entry to negatively
control the cell cycle, preventing the uncontrolled proliferation of tumor cells (Giacinti &
Giordano, 2006). Phosphorylation on serine-807 and serine-811 of pRb induced by
CDK4/6-cyclinD complex leads to functional inactivation of pRb, resulting in cell cycle
progression (Brantley & Harbour, 2000), while induction of dephosphorylation leads to
apoptosis (Adegbola & Pasternack, 2005). On the other hand, p21(Cip1/Waf1), which is
encoded by the gene CDKN1A, is a CDK inhibitor that regulates cell cycle progression
(Wade Harper, 1993). It has been found that p21 has a complex regulatory function on
CDK4/6: it can bind to CDK4/6-cyclinD1 complex, which stabilized and inactivated
CDK4/6 function to negatively regulate the G1 to S phase shift; it may in contrast activate
CDK4/6 at low level (Karimian et al., 2016). These cell cycle regulatory molecules may
have interactions with survivin. Survivin could interact with CDK4, leading to pRb
phosphorylation (Suzuki et al., 2000). Survivin/CDK4 complex formation may induce p21
released from its complex with CDK4 and interacts with mitochondrial procaspase 3 to
suppress Fas-mediated cell death (Suzuki et al., 2000). As supported by the bioinformatic
analysis data and further validation results, MX106-4C may induce cell apoptosis and
G0/G1 arrest in SW620/Ad300 cells via down regulating CDK4 and CDK6 leading to
hypophosphorylation of pRb. Although the change in p21 protein level was insignificant,
it is still possible that p21 is involved in MX106-4C-mediated cell apoptosis mechanism.
Inhibition of survivin by MX106-4C may result in caspase-3-activated cell apoptosis by
stabilizing p21/CDK4 complex and at the same time cause G0/G1 phase arrest.
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It was clearly observed that functional ABCB1 expression is required for MX106-4Cmediated cell apoptosis, cell cycle arrest, and the underlying CDK6 inhibition, pRb
dephosphorylation and caspase-3 activation, However, little has been revealed regarding
the precise role of ABCB1 efflux function and ATP hydrolysis in these selective effects
from MX106-4C. One possible explanation may be the ABCB1-dependent expression of
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). It has been
reported that functional ABCB1 plays a critical role in TRAIL expression, and inhibition
of ABCB1 activity could induce TRAIL expression and reduce binding of the TRAIL
ligand to death receptors (Souza et al., 2015). Survivin was also found to inhibit TRAILinduced apoptosis (Azuhata et al., 2006). As mutual regulations between survivin and
ABCB1 has been found on transcriptional levels but not on translational or posttranslational levels in cancer cells (Liu et al., 2010; Shi et al., 2007), survivin and ABCB1
might interact indirectly via involved signaling pathways like the TRAIL apoptotic
pathway. It may be hypothesized that MX106-4C could be involved in multiple
mechanisms such as triggering TRAIL-related apoptotic signal transduction, which
requires an intracellular environment with functional ABCB1, meanwhile causing survivin
inhibition that enhanced the activity of the apoptotic signal pathway. Further study is
needed to elucidate the roles of ABCB1 and survivin in the CS effect of MX106-4C.

Finally, as a CS agent, the potential of MX106-4C to synergistically inhibit heterogenetic
tumors with conventional anticancer drugs and to re-sensitize heterogenetic tumors to
ABCB1 substrate drug were proved. As long-term exposure to MX106-4C caused
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significantly reduced expression of ABCB1 in the cell population, it is reasonable that
MX106-4C could re-sensitize colon cancer cells to doxorubicin. Furthermore, considering
the limitation of 2D monolayer cell culture that the monolayer culture cells do not reflect
the natural structures of tumors and the cell-cell or cell-extracellular environment
interactions, and that the drug diffusion patterns are altered (Kapalczynska et al., 2018),
the 3D MCTSs model was used to mimic the tumor growth and sensitivity to MX106-4C
in vitro. It was proved that the selective toxicity of MX106-4C in vitro can be retained in
the 3D spheroid setting. It is encouraging that MX106-4C exhibited a good selectivity
against ABCB1 positive colon cancer cells and was relatively safe to normal colon cells.
Nevertheless, the normal cell line tested was colon fibroblast, whereas ABCB1 is
physiologically majorly expressed on the apical epithelial cells of colon tissue (Holohan et
al., 2013). Therefore, the toxicity of MX106-4C on colon cells expressing ABCB1 remains
uncertain. Future study should focus on further evaluation of the anti-cancer efficacy and
safety of MX106-4C in vivo.
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CHAPTER 5 SUMMARY
It has been characterized in this study that MX106-4C is a potent CS agent, which
selectively kills ABCB1 positive cells without affecting ABCB1 functions or subcellular
localization. Mechanistic study findings are illustrated in Figure 30. The selective toxicity
of MX106-4C is dependent on ABCB1 expression and requires functional ABCB1,
particularly the ATP hydrolysis, which could explain the ROS production induced by
MX106-4C in ABCB1 overexpressing cells. In addition, the selective cytotoxic effects of
MX106-4C could be associated with ABCB1-dependent functional inhibition on survivin,
leading to cell cycle arrest at G0/G1 phase and cell apoptosis, possibly via modulation on
p21-CDK4/6-pRb phosphorylation pathway and activation of caspases-3/7. However, it
remains a lot to be elucidated regarding the precise role of ABCB1 in MX106-4C-mediated
cell apoptosis, cell cycle arrest, and the molecular alterations on corresponding pathways.

As a CS agent, MX106-4C can be useful to treat colon cancer by synergistically killing
cancer cells when administrated with doxorubicin or re-sensitizing ABCB1 overexpressing
cells to substrate chemotherapeutic drugs. And most importantly, it has good selectivity for
ABCB1 positive colon cancer cells compared to normal colon cells.

Future studies will focus on further elucidation on the mechanism of action for MX106-4C
induced CS effect, particularly how ABCB1 function contributes to the toxicity effect.
Meanwhile, evaluation of the anti-cancer efficacy and safety of MX106-4C using in vivo
model is of necessity.
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Figure 30. Graphical summary of possible mechanisms involved in MX106-4Cinduced selective toxicity against ABCB1 positive colon cancer cells.
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